

- Aldabe, R., Barco, A. & Carrasco, L. (1996).** Membrane permeabilization by poliovirus proteins 2B and 2BC. *J Biol Chem* **271**, 23134-23137.
- Arroyo, J., Boceta, M., González, Michel, M. & Carrasco, L. (1995).** Membrane permeabilization by different regions of the human immunodeficiency virus type 1 transmembrane glycoprotein gp41. *J Virol* **69**, 4095-4102.
- Au, K. S., Mattion, N. M. & Estes, M. K. (1993).** A subviral particle binding domain on the rotavirus nonstructural glycoprotein NS28. *Virology* **194**, 665-673.
- Balasuriya, U. B., Nadler, S. A., Wilson, W. C., Pritchard, L. I., Smythe, A. B., Savini, G., Monaco, F., de Santis, P., Zhang, N., Tabachnick, W. J. & MacLachlan, N. J. (2008).** The NS3 proteins of global strains of bluetongue virus evolve into regional topotypes through negative (purifying) selection. *Vet Microbiol* **126**, 91-100.
- Ball, J. M., Tian, P., Zeng, C. Q., Morris, A. P. & Estes, M. K. (1996).** Age-dependent diarrhea induced by a rotaviral nonstructural glycoprotein. *Science* **272**, 101-104.
- Bansal, O. B., Stokes, A., Bansal, A., Bishop, D. & Roy, P. (1998).** Membrane organization of bluetongue virus non-structural glycoprotein NS3. *J Virol* **72**, 3362-3369.
- Batten, C. A., Maan, S., Shaw, A. E., Maan, N. S. & Mertens, P. P. (2008).** A European field strain of bluetongue virus derived from two parental vaccine strains by genome segment reassortment. *Virus Res*.
- Beaton, A. R., Rodriguez, J., Reddy, Y. K. & Roy, P. (2002).** The membrane trafficking protein calpastatin forms a complex with bluetongue virus protein NS3 and mediates virus release. *Proc Natl Acad Sci U S A* **99**, 13154-13159.
- Bechinger, B. (2008).** A dynamic view of peptides and proteins in membranes. *Cell Mol Life Sci* **19**, 3028-3039.
- Bentley, L., Fehrson, J., Jordaan, F., Huismans, H. & du Plessis, D. H. (2000).** Identification of antigenic regions on VP2 of African horsesickness virus serotype 3 by using phage-displayed epitope libraries. *J Gen Virol* **81**, 993-1000.
- Berkova, Z., Crawford, S. E., Blutt, S. E., Morris, A. P. & Estes, M. K. (2007).** Expression of rotavirus NSP4 alters the actin network organization through the actin remodeling protein cofilin. *J Virol* **81**, 3545-3553.
- Berkova, Z., Crawford, S. E., Trugnan, G., Yoshimori, T., Morris, A. P. & Estes, M. K. (2006).** Rotavirus NSP4 induces a novel vesicular compartment regulated by calcium and associated with viroplasms. *J Virol* **80**, 6061-6071.
- Berkova, Z., Morris, A. P. & Estes, M. K. (2003).** Cytoplasmic calcium measurement in rotavirus enterotoxin-enhanced green fluorescent protein (NSP4-EGFP) expressing cells loaded with Fura-2. *Cell Calcium* **34**, 55-68.
- Bhattacharya, B. & Roy, P. (2008).** Bluetongue virus outer capsid protein VP5 interacts with membrane lipid rafts via a SNARE domain. *J Virol* **82**, 10600-10612.
- Bodelón, G., Labrada, L., Martínez-Costas, J. & Benavente, J. (2002).** Modification of late membrane permeability in avian reovirus-infected cells. *J Biol Chem* **277**, 17789-17796.
- Borghani, M. A., Mori, Y., El-Mahmoudy, A. B., Ito, N., Sugiyama, M., Takewaki, T. & Minamoto, N. (2007).** Induction of nitric oxide synthase by rotavirus enterotoxin NSP4: implication for rotavirus pathogenicity. *J Gen Virol* **88**, 2064-2072.
- Bowie, J. U. (2005).** Solving the membrane protein folding problem. *Nature* **438**, 581-589.
- Boyce, M., Celma, C. C. & Roy, P. (2008).** Development of reverse genetics systems for bluetongue virus: recovery of infectious virus from synthetic RNA transcripts. *J Virol* **82**, 8339-8348.
- Brass, A. L., Dykxhoorn, D. M., Benita, Y., Yan, N., Engelman, A., Xavier, R. J., Lieberman, J. & Elledge, S. J. (2008).** Identification of host proteins required for HIV infection through a functional genomic screen. *Science* **319**, 921-926.
- Bremer, C. W. (1976).** A gel electrophoretic study of the protein and nucleic acid components of African horsesickness virus. *Onderstepoort J Vet Res* **43**, 193-199.
- Brignati, M. J., Loomis, J. S., Wills, J. W. & Courtney, R. J. (2003).** Membrane association of VP22, a herpes simplex virus type 1 tegument protein. *J Virol* **77**, 4888-4898.
- Briones, C., de Vicente, A., Molina-París, C. & Domingo, E. (2006).** Minority memory genomes can influence the evolution of HIV-1 quasispecies *in vivo*. *Gene* **384**, 129-138.
- Browne, E. P., Bellamy, A. R. & Taylor, J. A. (2000).** Membrane-destabilizing activity of rotavirus NSP4 is mediated by a membrane-proximal amphipathic domain. *J Gen Virol* **81**, 1955-1959.
- Bugarcic, A. & Taylor, J. A. (2006).** Rotavirus nonstructural glycoprotein NSP4 is secreted from the apical surfaces of polarized epithelial cells. *J Virol* **80**, 12343-12349.
- Burrage, T. G. & Laegried, W. W. (1994).** African horse sickness: pathogenesis and immunity. *Comp Immunol Microbiol Infect Dis* **17**, 275-285.

- Burrage, T. G., Trevejo, R., Stone-Marschat, M. & Laegreid, W. W. (1993).** Neutralizing epitopes of African horsesickness virus serotype 4 are located on VP2. *Virology* **196**, 799-803.
- Butan, C., van der Zandt, H. & Tucker, P. A. (2004).** Structure and assembly of the RNA binding domain of bluetongue virus non-structural protein 2. *J Biol Chem* **279**, 37613-37621.
- Carrasco, L. (1995).** Modification of membrane permeability by animal viruses. *Adv Virus Res* **45**, 61-112.
- Cheung, L., McLain, L., Hollier, M. J., Reading, S. A. & Dimmock, N. J. (2005).** Part of the C-terminal tail of the envelope gp41 transmembrane glycoprotein of human immunodeficiency virus type 1 is exposed on the surface of infected cells and is involved in virus-mediated cell fusion. *J Gen Virol* **86**, 131-138.
- Chuma, T., Le Blois, H., Sanchez-Vizcaino, J. M., Diaz-Laviada, M. & Roy, P. (1992).** Expression of the major core antigen VP7 of African horsesickness virus by a recombinant baculovirus and its use as a group-specific diagnostic reagent. *J Gen Virol* **73 ( Pt 4)**, 925-931.
- Chwetzoff, S. & Trugnan, G. (2006).** Rotavirus assembly: an alternative model that utilizes an atypical trafficking pathway. *Curr Top Microbiol Immunol* **309**, 245-261.
- Ciarlet, M., Liprandi, F., Conner, M. E. & Estes, M. K. (2000).** Species specificity and interspecies relatedness of NSP4 genetic groups by comparative NSP4 sequence analyses of animal rotaviruses. *Arch Virol* **145**, 371-383.
- Ciccaglione, A. R., Costantino, A., Marcantinio, C., Equestre, M., Geraci, A. & Rapicetta, M. (2001).** Mutagenesis of hepatitis C virus E1 protein affects its membrane-permeabilizing activity. *J Gen Virol* **82**, 2243-2250.
- Ciccaglione, A. R., Marcantinio, C., Costantino, A., Equestre, M., Geraci, A. & Rapicetta, M. (1998).** Hepatitis C virus E1 protein induces modification of membrane permeability in *E. coli* cells. *Virology* **250**, 1-8.
- Coetzer, J. A. & Erasmus, B. J. (1994).** African horsesickness. In *Infectious Diseases of Livestock with Special Reference to Southern Africa*, pp. 460-475. Edited by J. A. Coetzer, C. R. Thomson & R. C. Tustin. New York: Oxford University Press.
- Coetzer, J. A. W. & Guthrie, A. J. (2004).** African horsesickness. In *Infectious Diseases Of Livestock*, pp. 1231-1246. Edited by J. A. W. Coetzer & R. C. Tustin. Cape Town: Oxford University Press.
- Cokol, M., Nair, R. & Rost, B. (2000).** Finding nuclear localization signals. *EMBO Rep* **1**, 411-415.
- Corse, E. & Machamer, C. E. (2000).** Infectious bronchitis virus E protein is targeted to the Golgi complex and directs release of virus-like particles. *J Virol* **74**, 4319 - 4326.
- Cowley, J. A. & Gorman, B. M. (1987).** Genetic reassortants for identification of the genome segment coding for the bluetongue virus hemagglutinin. *J Virol* **61**, 2304-2306.
- Cuadras, M. A., Bordier, B. B., Zambrano, J. L., Ludert, J. E. & Greenberg, H. B. (2006).** Dissecting rotavirus particle-raft interaction with small interfering RNAs: insights into rotavirus transit through the secretory pathway. *J Virol* **80**, 3935-3946.
- De Jong, A. S., Melchers, W. J. G., Glaudemans, D. H. R. F., Peter H. G. M. Willems & van Kuppeveld, F. J. M. (2004).** Mutational analysis of different regions in the coxsackievirus 2B protein. *J Biol Chem* **279**, 19924-19935.
- De Jong, A. S., Wessels, E., Dijkman, H. B. P. M., Galama, J. M. D., Melchers, W. J. G., Willems, P. H. G. M. & van Kuppeveld, F. J. M. (2003).** Determinants for membrane association and permeabilization of the coxsackievirus 2B protein and the identification of the golgi complex as the target organelle. *J Biol Chem* **278**, 1012-1021.
- De Vries, W., Haasnoot, J., van der Velden, J., van Montfort, T., Zorgdrager, F., Paxton, W., Cornelissen, M., van Kuppeveld, F., de Haan, P. & Berkhout, B. (2008).** Increased virus replication in mammalian cells by blocking the intracellular innate defence responses. *Gene Therapy* **15**, 545-552.
- De Waal, P. J. & Huismans, H. (2005).** Characterization of the nucleic acid binding activity of inner core protein VP6 of African horse sickness virus. *Arch Virol* **150**, 2037-2050.
- DeDiego, M. L., Álvarez, E., Almazán, F., Rejas, M. T., Lamirande, E., Roberts, A., Shieh, W., Zaki, S. R., Subbarao, K. & Enjuanes, L. (2007).** A severe acute respiratory syndrome coronavirus that lacks the E gene is attenuated in vitro and in vivo. *J Virol* **81**, 1701-1713.
- Delmas, O., Durand-Schneider, A. M., Cohen, J., Colard, O. & Trugnan, G. (2004a).** Spike protein VP4 assembly with maturing rotavirus requires a postendoplasmic reticulum event in polarized caco-2 cells. *J Virol* **78**, 10987-10994.
- Delmas, O., Gardet, A., Chwetzoff, S., Breton, M., Cohen, J., Colard, O., Sapin, C. & Trugnan, G. (2004b).** Different ways to reach the top of a cell. Analysis of rotavirus assembly and targeting in human intestinal cells reveals an original raft-dependent, Golgi-independent apical targeting pathway. *Virology* **327**, 157-161.
- DeMaula, C. D., Jutila, M. A., Wilson, D. W. & MacLachlan, N. J. (2001).** Infection kinetics, prostacyclin release and cytokine-mediated modulation of the mechanism of cell death during bluetongue virus infection of cultured ovine and bovine pulmonary artery and lung microvascular endothelial cells. *J Gen Virol* **82**, 787-794.

- DeMaula, C. D., Leutenegger, C. M., Jutila, M. A. & MacLachlan, N. J. (2002).** Bluetongue virus-induced activation of primary bovine lung microvascular endothelial cells. *Vet Immunol Immunopathol* **86**, 147-157.
- Dennehy, P. H. (2008).** Rotavirus vaccines: an overview. *Clin Microbiol Rev* **21**, 198-208.
- Devaney, M. A., Kendall, J. & Grubman, M. J. (1988).** Characterization of a nonstructural phosphoprotein of two orbiviruses. *Virus Res* **11**, 151-164.
- Domingo, E., Escarmis, C., Sevilla, N., Moya, A., Elena, S. F., Quer, J., Novella, I. S. & Holland, J. J. (1996).** Basic concepts in RNA virus evolution. *FASEB Journal* **10**, 859-864.
- Domingo, E. & Holland, J. J. (1997).** RNA virus mutations and fitness for survival. *Annu Rev Microbiol* **51**, 151-178.
- Dowling, W., Denisova, E., Lamonica, R. & Mackow, E. (2000).** Selective membrane permeabilization by the rotavirus VP5 protein is abrogated by mutations in an internal hydrophobic domain. *J Virol* **74**, 6368-6376.
- Du Plessis, M., Cloete, M., Aitchison, H. & van Dijk, A. A. (1998).** Protein aggregation complicates the development of baculovirus-expressed African horsesickness virus serotype 5 VP2 subunit vaccines. *Onderstepoort J Vet Res* **65**, 321-329.
- Eaton, B. T., Hyatt, A. D. & Brookes, S. M. (1990).** The replication of bluetongue virus. *Curr Top Microbiol Immunol* **162**, 89-118.
- Erasmus, B. J. (1998).** African horse sickness. In *US Animal Health Association, Committee on Foreign Animal Disease Foreign animal diseases: the gray book*, 6 edn, p. Part IV. Richmond, VA: US Animal Health Assoc.
- Estes, M. K. (2001).** Rotaviruses and their replication. In *Fields virology*, 4 edn, pp. 1747–1785. Edited by D. M. Knipe, P. M. Howley, D. E. Griffin, R. A. Lamb, M. A. Martin, B. Roizman & S. E. Straus. Philadelphia, PA: Lippincott Williams & Wilkins.
- Fillmore, G. C., Lin, H. & Li, J. K. (2002).** Localization of the single-stranded RNA-binding domains of bluetongue virus nonstructural protein NS2. *J Virol* **76**, 499-506.
- Firth, A. E. (2008).** Bioinformatic analysis suggests that the Orbivirus VP6 cistron encodes an overlapping gene. *Virol J* **5**, 48.
- Forzan, M., Marsh, M. & Roy, P. (2007).** Bluetongue virus entry into cells. *J Virol* **81**, 4819-4827.
- Forzan, M., Wirblich, C. & Roy, P. (2004).** A capsid protein of nonenveloped Bluetongue virus exhibits membrane fusion activity. *Proc Natl Acad Sci U S A* **101**, 2100-2105.
- Franco, R., Bortner, C. D. & Cidlowski, J. A. (2006).** Potential roles of electrogenic ion transport and plasma membrane depolarization in apoptosis. *J Membr Biol* **209**, 43–58.
- French, T. J., Inumaru, S. & Roy, P. (1989).** Expression of two related non-structural proteins of bluetongue virus (BTV) type 10 in insect cells by a recombinant baculovirus: Production of polyclonal ascitic fluid and characterization of the gene product in BTV-infected BHK cells. *J Virol* **63**, 3270-3278.
- Garry, R. F., Bishop, J. M., Parker, S., Westbrook, K., Lewis, G. & Waite, M. R. (1979).** Na<sup>+</sup> and K<sup>+</sup> concentrations and the regulation of protein synthesis in Sindbis virus-infected chick cells. *Virology* **96**, 108-120.
- Ghosh, M. K., Borca, M. V. & Roy, P. (2002a).** Virus-derived tubular structure displaying foreign sequences on the surface elicit CD4+ Th cell and protective humoral responses. *Virology* **302**, 383-392.
- Ghosh, M. K., De'riaud, E., Saron, M. F., Lo-Man, R., Henry, T., Jiao, X., Roy, P. & Leclerc, C. (2002b).** Induction of protective antiviral cytotoxic T cells by a tubular structure capable of carrying large foreign sequences. *Vaccine* **20**, 1369-1377.
- Gomez-Villamandos, J. C., Sanchez, C., Carrasco, L., Laviada, M. M., Bautista, M. J., Martinez-Torrecuadrada, J., Sanchez-Vizcaino, J. M. & Sierra, M. A. (1999).** Pathogenesis of African horse sickness: ultrastructural study of the capillaries in experimental infection. *J Comp Pathol* **121**, 101-116.
- Gonzalez, M. A. & Carrasco, L. (2001).** Human immunodeficiency virus type 1 vpu protein affects Sindbis virus glycoprotein processing and enhances membrane permeabilization. *Virology* **279**, 201-209.
- Gonzalez, M. E. & Carrasco, L. (2003).** Viroporins. *FEBS Lett* **552**, 28-34.
- Gould, E. A. & Higgs, S. (2009).** Impact of climate change and other factors on emerging arbovirus diseases. *Trans R Soc Trop Med Hyg* **103**, 109-121.
- Greene, I. P., Wang, E., Deardorff, E. R., Milleron, R., Domingo, E. & Weaver, S. C. (2005).** Effect of alternating passage on adaptation of sindbis virus to vertebrate and invertebrate cells. *J Virol* **79**, 14253-14260.
- Grimes, J. M., Burroughs, J. N., Gouet, P., Diprose, J. M., Malby, R., Zientara, S., Mertens, P. P. & Stuart, D. I. (1998).** The atomic structure of the bluetongue virus core. *Nature* **395**, 470-478.
- Guinea, R. & Carrasco, L. (1994).** Influenza virus M2 protein modifies membrane permeability in *E. coli* cells. *FEBS Letters* **343**, 242-246.

- Halaihel, N., Lievin, V., Ball, J. M., Estes, M. K., Alvarado, F. & Vasseur, M. (2000).** Direct inhibitory effect of rotavirus NSP4(114-135) peptide on the Na(+)-D-glucose symporter of rabbit intestinal brush border membrane. *J Virol* **74**, 9464-9470.
- Han, Z. & Harty, R. N. (2004).** The NS3 protein of bluetongue virus exhibits viroporin-like properties. *J Biol Chem* **279**, 43092-43097.
- Hassan, S. H., Wirblich, C., Forzan, M. & Roy, P. (2001).** Expression and functional characterization of bluetongue virus VP5 protein: role in cellular permeabilization. *J Virol* **75**, 8356-8367.
- Hassan, S. S. & Roy, P. (1999).** Expression and functional characterization of bluetongue virus VP2 protein: role in cell entry. *J Virol* **73**, 9832-9842.
- Hatherell, T. (2007).** An investigation into the subcellular localisation of nonstructural protein NS3 of African horsesickness virus. Pretoria: University of Pretoria.
- Hou, Z., Huang, Y., Huan, Y., Pang, W., Meng, M., Wang, P., Yang, M., Jiang, L., Cao, X. & Wu, K. K. (2008).** Anti-NSP4 antibody can block rotavirus-induced diarrhea in mice. *J Pediatr Gastroenterol Nutr* **46**, 376-385.
- Howell, P. G. (1962).** The isolation and identification of further antigenic types of African horse sickness virus. *Onderstepoort J Vet Res* **29**, 139-149.
- Howerth, E. W. & Tyler, D. E. (1988).** Experimentally induced bluetongue virus infection in white-tailed deer: ultrastructural findings. *Am J Vet Res* **49**, 1914-1922.
- Huang, H., Schroeder, F., Estes, M. K., McPherson, T. & Ball, J. M. (2004).** Interaction(s) of rotavirus non-structural protein 4 (NSP4) C-terminal peptides with model membranes. *Biochem J* **380**, 723-733.
- Huang, H., Schroeder, F., Zeng, C., Estes, M. K., Schoer, J. & Ball, J. A. (2001).** Membrane interactions of a novel viral enterotoxin: rotavirus non-structural glycoprotein NSP4. *Biochemistry* **40**, 4169-4180.
- Huismans, H. (1979).** Protein synthesis in bluetongue virus-infected cells. *Virology* **92**, 385-396.
- Huismans, H. & Els, H. J. (1979).** Characterization of the tubules associated with the replication of three different orbiviruses. *Virology* **92**, 397-406.
- Hyatt, A. D., Eaton, B. T. & Brookes, S. M. (1989).** The release of bluetongue virus from infected cells and their superinfection by progeny virus. *Virology* **173**, 21-34.
- Hyatt, A. D., Gould, A. R., Coupar, B. & Eaton, B. T. (1991).** Localization of the non-structural protein NS3 in bluetongue virus-infected cells. *J Gen Virol* **72**, 2263-2267.
- Hyatt, A. D., Zhao, Y. & Roy, P. (1993).** Release of bluetongue virus-like particles from insect cells is mediated by BTV non-structural protein NS3/NS3A. *Virology* **193**, 592-603.
- Isherwood, B. J. & Patel, A. H. (2005).** Analysis of the processing and transmembrane topology of the E2p7 protein of hepatitis C virus. *J Gen Virol* **86**, 667-676.
- Iturriza-Gómara, M., Isherwood, B., Desselberger, U. & Gray, J. J. (2001).** Reassortment *in vivo*: Driving force for diversity of human rotavirus strains isolated in the United Kingdom between 1995 and 1999. *J Virol* **75**, 3696-3705.
- Jourdan, N., Maurice, M., Delautier, D., Quero, A. M., Servin, A. L. & Trugnan, G. (1997).** Rotavirus is released from the apical surface of cultured human intestinal cells through nonconventional vesicular transport that bypasses the Golgi apparatus. *J Virol* **71**, 8268-8278.
- Kahlon, J., Siugiyama, K. & Roy, P. (1983).** Molecular basis of bluetongue virus neutralization. *J Virol* **48**, 627-632.
- Kar, A. K., Bhattacharya, B. & Roy, P. (2007).** Bluetongue virus RNA binding protein NS2 is a modulator of viral replication and assembly. *BMC Mol Biol* **8**, 4.
- Kirkwood, C. D. & Palombo, E. A. (1997).** Genetic characterization of the rotavirus nonstructural protein, NSP4. *Virology* **236**, 258-265.
- Koekemoer, J. J., Potgieter, A. C., Paweska, J. T. & van Dijk, A. A. (2000).** Development of probes for typing African horsesickness virus isolates using a complete set of cloned VP2-genes. *J Virol Methods* **88**, 135-144.
- Krogh, A., Larsson, B., von Heijne, G. & Sonnhammer, E. L. (2001).** Predicting transmembrane protein topology with a hidden Markov model: application to complete genomes. *J Mol Biol* **305**, 567-580.
- Kuo, L. & Masters, P. S. (2003).** The small envelope protein E is not essential for murine coronavirus replication. *J Virol* **77**, 4597-4608.
- Laegreid, W. W., Burrage, T. G., Stone-Marschat, M. & Skowronek, A. (1992a).** Electron microscopic evidence for endothelial infection by African horsesickness virus. *Vet Pathol* **29**, 554-556.
- Laegreid, W. W., Skowronek, A., Stone-Marschat, M. & Burrage, T. (1993).** Characterization of virulence variants of African horsesickness virus. *Virology* **195**, 836-839.
- Laegreid, W. W., Stone-Marschat, M., Skowronek, A. & Burrage, T. (1992b).** Infection of endothelial cells by African horse sickness viruses. In *Bluetongue, African Horse Sickness, and Related Orbiviruses*, pp. 807-814. Edited by T. E. Walton & B. I. Osburn. Florida: CRC Press.
- Lama, J. & Carrasco, L. (1995).** Mutations in the hydrophobic domain of poliovirus protein 3AB abrogate its permeabilising activity. *FEBS Letters* **367**, 5-11.

- Lambert, C. & Prange, R. (2001).** Dual topology of the hepatitis B virus large envelope protein: determinants influencing post-translational pre-S translocation. *J Biol Chem* **276**, 22265-22272.
- Liao, Y., Yuan, Q., Torres, J., Tam, J. P. & Liu, D. X. (2006).** Biochemical and functional characterization of the membrane association and membrane permeabilizing activity of the severe acute respiratory syndrome coronavirus envelope protein. *Virology* **349** 264-275.
- Liu, D. X., Yuan, Q. & Liaob, Y. (2007).** Coronavirus envelope protein: a small membrane protein with multiple functions. *Cell Mol Life Sci* **64**, 2043 - 2048.
- Loewy, A., Smyth, J., von Bonsdorff, C. H., Liljestrom, P. & Schlesinger, M. J. (1995).** The 6-kilodalton membrane protein of Semliki Forest virus is involved in the budding process. *J Virol* **69**, 469-475.
- Lopez, T., Camacho, M., Zayas, M., Najera, R., Sanchez, R., Arias, C. F. & Lopez, S. (2005).** Silencing the morphogenesis of rotavirus. *J Virol* **79**, 184-192.
- Lundin, M., Monne, M., Widell, A., von Heijne, G. & Persson, M. A. (2003).** Topology of the membrane-associated hepatitis C virus protein NS4B. *J Virol* **77**, 5428-5438.
- Lymeropoulos, K., Noad, R., Tosi, S., Nethisinghe, S., Brierley, I. & Roy, P. (2006).** Specific binding of Bluetongue virus NS2 to different viral plus-strand RNAs. *Virology* **353**, 17-26.
- Maass, D. R. & Atkinson, P. H. (1990).** Rotavirus proteins VP7, NS28, and VP4 form oligomeric structures. *J Virol* **64**, 2632-2641.
- MacLachlan, N. J. (1994).** The pathogenesis and immunology of bluetongue virus infection of ruminants. *Comp Immunol Microbiol Infect Dis* **17**, 197-206.
- MacLachlan, N. J., Balasuriya, U. B., Davis, N. L., Collier, M., Johnston, R. E., Ferraro, G. L. & Guthrie, A. J. (2007).** Experiences with new generation vaccines against equine viral arteritis, West Nile disease and African horse sickness. *Vaccine* **25**, 5577-5582.
- Madan, V., Castello, A. & Carrasco, L. (2008).** Viroporins from RNA viruses induce caspase-dependent apoptosis. *Cell Microbiol* **10**, 437-451.
- Madan, V., Garcia Mde, J., Sanz, M. A. & Carrasco, L. (2005a).** Viroporin activity of murine hepatitis virus E protein. *FEBS Lett* **579**, 3607-3612.
- Madan, V., Sánchez-Martínez, S., Vedovato, N., Rispoli, G., Carrasco, L. & Nieva, J. L. (2007).** Plasma membrane-porating domain in poliovirus 2B protein. A short peptide mimics viroporin activity. *J Mol Biol* **374**, 951-964.
- Madan, V., Sanz, M. A. & Carrasco, L. (2005b).** Requirement of the vesicular system for membrane permeabilization by Sindbis virus. *Virology* **332**, 307-315.
- Mahbub Alam, M., Kobayashi, N., Ishino, M., Naik, T. N. & Taniguchi, K. (2006).** Analysis of genetic factors related to preferential selection of the NSP1 gene segment observed in mixed infection and multiple passage of rotaviruses. *Arch Virol* **151**, 2149-2159.
- Maree, F. F. & Huismans, H. (1997).** Characterization of tubular structures composed of nonstructural protein NS1 of African horsesickness virus expressed in insect cells. *J Gen Virol* **78**, 1077-1082.
- Maree, S., Durbach, S. & Huismans, H. (1998).** Intracellular production of African horsesickness virus core-like particles by expression of the two major core proteins, VP3 and VP7, in insect cells. *J Gen Virol* **79 ( Pt 2)**, 333-337.
- Marheineke, K., Grünwald, S., Christie, W. & Reiländer, H. (1998).** Lipid composition of *Spodoptera frugiperda* (Sf9) and *Trichoplusia ni* (Tn) insect cells used for baculovirus infection. *FEBS Lett* **441**, 49-52.
- Martin, L. A., Meyer, A. J., O'Hara, R. S., Fu, H., Mellor, P. S., Knowles, N. J. & Mertens, P. P. (1998).** Phylogenetic analysis of African horse sickness virus segment 10: sequence variation, virulence characteristics and cell exit. . *Arch Virol (Suppl)* **14**, 281-293.
- Martinez-Torrecuadrada, J. L. & Casal, J. I. (1995).** Identification of a linear neutralization domain in the protein VP2 of African horse sickness virus. *Virology* **210**, 391-399.
- Martinez-Torrecuadrada, J. L., Diaz-Laviada, M., Roy, P., Sanchez, C., Vela, C., Sanchez-Vizcaino, J. M. & Casal, J. I. (1996).** Full protection against African horsesickness (AHS) in horses induced by baculovirus-derived AHS virus serotype 4 VP2, VP5 and VP7. *J Gen Virol* **77 ( Pt 6)**, 1211-1221.
- Martinez-Torrecuadrada, J. L., Iwata, H., Venteo, A., Casal, I. & Roy, P. (1994).** Expression and characterization of the two outer capsid proteins of African horsesickness virus: the role of VP2 in virus neutralization. *Virology* **202**, 348-359.
- Martinez-Torrecuadrada, J. L., Langeveld, J. P., Meloen, R. H. & Casal, J. I. (2001).** Definition of neutralizing sites on African horse sickness virus serotype 4 VP2 at the level of peptides. *J Gen Virol* **82**, 2415-2424.
- Martinez-Torrecuadrada, J. L., Langeveld, J. P., Venteo, A., Sanz, A., Dalsgaard, K., Hamilton, W. D., Meloen, R. H. & Casal, J. I. (1999).** Antigenic profile of African horse sickness virus serotype 4 VP5 and identification of a neutralizing epitope shared with bluetongue virus and epizootic hemorrhagic disease virus. *Virology* **257**, 449-459.
- Maruri-Avidal, L., Lopez, S. & Arias, C. F. (2008).** Endoplasmic reticulum chaperones are involved in the morphogenesis of rotavirus infectious particles. *J Virol* **82**, 5368-5380.

- Matsumoto, T., Takahashi, H. & Fujiwara, H. (2004).** Targeted nuclear import of open reading frame 1 protein is required for *in vivo* retrotransposition of a telomere-specific non-long terminal repeat retrotransposon. *Mol Cell Biol* **24**, 105-122.
- McGinnes, L. W., Reitter, J. N., Gravel, K. & Morrison, T. G. (2003).** Evidence for mixed membrane topology of the Newcastle disease virus fusion protein. *J Virol* **77**, 1951-1963.
- Meiswinkel, R. (1998).** The 1996 outbreak of African horse sickness in South Africa--the entomological perspective. *Arch Virol Suppl* **14**, 69-83.
- Mellor, P. S. & Hamblin, C. (2004).** African horse sickness. *Vet Res* **35**, 445-466.
- Mellor, P. S., Rawlings, P., Baylis, M. & Wellby, M. P. (1998).** Effect of temperature on African horse sickness virus infection in *Culicoides*. *Arch Virol Suppl* **14**, 155-163.
- Melton, J. V., Ewart, G. D., Weir, R. C., Board, P. G., Lee, E. & Gage, P. W. (2002).** Alphavirus 6 K proteins form ion channels. *J Biol Chem* **277**, 46923-46931.
- Mertens, P. (2004).** The dsRNA viruses. *Virus Res* **101**, 3-13.
- Mertens, P. P. & Diprose, J. (2004).** The bluetongue virus core: a nano-scale transcription machine. *Virus Res* **101**, 29-43.
- Mertens, P. P. C., Brown, F. & Sangar, D. V. (1984).** Assignment of the genome segments of bluetongue virus type I to the proteins which they encode. *Virology* **135**, 207-217.
- Miller, S., Sparacio, S. & Bartenschlager, R. (2006).** Subcellular localization and membrane topology of the Dengue virus type 2 non-structural protein 4B. *J Biol Chem* **281**, 8854-8863.
- Mir, K. D., Parr, R. D., Schroeder, F. & Ball, J. M. (2007).** Rotavirus NSP4 interacts with both the amino- and carboxyl-termini of caveolin-1. *Virus Res* **126**, 106-115.
- Mirazimi, A., Nilsson, M. & Svensson, L. (1998).** The molecular chaperone calnexin interacts with the NSP4 enterotoxin of rotavirus *in vivo* and *in vitro*. *J Virol* **72**, 8705-8709.
- Mirazimi, A. & Svensson, L. (1998).** Carbohydrates facilitate correct disulfide bond formation and folding of rotavirus VP7. *J Virol* **72**, 3887-3892.
- Miwa, N., Uebi, T. & Kawamura, S. (2008).** S100-annexin complexes - biology of conditional association. *FEBS Journal* **275**, 4945-4955.
- Modrof, J., Lymeropoulos, K. & Roy, P. (2005).** Phosphorylation of bluetongue virus nonstructural protein 2 is essential for formation of viral inclusion bodies. *J Virol* **79**, 10023-10031.
- Monastyrskaya, K., Booth, T., Nel, L. & Roy, P. (1994).** Mutation of either of two cysteine residues or deletion of the amino or carboxy terminus of nonstructural protein NS1 of bluetongue virus abrogates virus-specified tubule formation in insect cells. *J Virol* **68**, 2169-2178.
- Moody, M. D. & Joklik, W. K. (1989).** The function of reovirus proteins during the reovirus multiplication cycle: analysis using monoreassortants. *Virology* **173**, 437-446.
- Mortola, E., Noad, R. & Roy, P. (2004).** Bluetongue virus outer capsid proteins are sufficient to trigger apoptosis in mammalian cells. *J Virol* **78**, 2875-2883.
- Murphy, A. & Roy, P. (2008).** Manipulation of the bluetongue virus tubules for immunogen delivery. *Future Microbiol* **3**, 351-359.
- Nagaleekar, V. K., Tiwari, A. K., Kataria, R. S., Bais, M. V., Ravindra, P. V. & Kumar, S. (2007).** Bluetongue virus induces apoptosis in cultured mammalian cells by both caspase-dependent extrinsic and intrinsic apoptotic pathways. *Arch Virol* **152**, 1751-1756.
- Nal, B., Chan, C., Kien, F., Siu, L., Tse, J., Chu, K., Kam, J., Staropoli, I., Crescenzo-Chaigne, B., Escriou, N., van der Werf, S., Yuen, K. Y. & Altmyer, R. (2005).** Differential maturation and subcellular localization of severe acute respiratory syndrome coronavirus surface proteins S, M and E. *J Gen Virol* **86**, 1423 - 1434.
- Newton, K., Meyer, J. C., Bellamy, A. R. & Taylor, J. A. (1997).** Rotavirus nonstructural glycoprotein NSP4 alters plasma membrane permeability in mammalian cells. *J Virol* **71**, 9458-9465.
- O'Brien, J. A., Taylor, J. A. & Bellamy, A. R. (2000).** Probing the structure of rotavirus NSP4: a short sequence at the extreme C terminus mediates binding to the inner capsid particle. *J Virol* **74**, 5388-5394.
- O'Hara, R. S., Meyer, A. J., Burroughs, J. N., Pullen, L., Martin, L. A. & Mertens, P. P. (1998).** Development of a mouse model system, coding assignments and identification of the genome segments controlling virulence of African horse sickness virus serotypes 3 and 8. *Arch Virol (Suppl)* **14**, 259-279.
- Owens, R. J., Limn, C. & Roy, P. (2004).** Role of an arbovirus nonstructural protein in cellular pathogenesis and virus release. *J Virol* **78**, 6649-6656.
- Paclet, M., Henderson, L. M., Campion, Y., Morel, F. & Dagher, M. (2004).** Localization of Nox2 N-terminus using polyclonal anti-peptide antibodies. *Biochem J* **382**, 981-986.
- Pappas, C., Aguilar, P. V., Basler, C. F., Solorzano, A., Zeng, H., Perrone, L. A., Palese, P., Garcia-Sastre, A., Katz, J. M. & Tumpey, T. M. (2008).** Single gene reassortants identify a critical role for PB1, HA, and NA in the high virulence of the 1918 pandemic influenza virus. *Proc Natl Acad Sci U S A* **105**, 3064-3069.

- Parks, C. L., Latham, T., Cahill, A., O'Neill R. E., Passarotti, C. J., Buonagurio, D. A., Bechert, T. M., D'Arco, G. A., Neumann, G., Destefano, J., Arendt, H. E., Obregon, J., Shuttyak, L., Hamm, S., Sidhu, M. S., Zamb, T. J. & Udem, S. A. (2007).** Phenotypic properties resulting from directed gene segment reassortment between wild-type A/Sydney/5/97 influenza virus and the live attenuated vaccine strain. *Virology* **367**, 275-287.
- Parr, R. D., Storey, S. M., Mitchell, D. M., McIntosh, A. L., Zhou, M., Mir, K. D. & Ball, J. M. (2006).** The rotavirus enterotoxin NSP4 directly interacts with the caveolar structural protein caveolin-1. *J Virol* **80**, 2842-2854.
- Paterson, R. G., Takeda, M., Ohigashi, Y., Pinto, L. H. & Lamba, R. A. (2003).** Influenza B virus BM2 protein is an oligomeric integral membrane protein expressed at the cell surface. *Virology* **306**, 7-17.
- Pierce, C. M., Balasuriya, U. B. & MacLachlan, N. J. (1998).** Phylogenetic analysis of the S10 gene of field and laboratory strains of bluetongue virus from the United States. *Virus Res* **55**, 15-27.
- Potgieter, A. C., Cloete, M., Pretorius, P. J. & van Dijk, A. A. (2003).** A first full outer capsid protein sequence data-set in the Orbivirus genus (family Reoviridae): cloning, sequencing, expression and analysis of a complete set of full-length outer capsid VP2 genes of the nine African horsesickness virus serotypes. *J Gen Virol* **84**, 1317-1326.
- Potgieter, A. C., Steele, A. D. & van Dijk, A. A. (2002).** Cloning of complete genome sets of six dsRNA viruses using an improved cloning method for large dsRNA genes. *J Gen Virol* **83**, 2215-2223.
- Purse, B. I. V., Mellor, P. S., Rogers, D. J., Samuel, A. R., Mertens, P. P. & Baylis, M. (2005).** Climate change and the recent emergence of bluetongue in Europe. *Nat Rev Microbiol* **3**, 171-181.
- Quan, M., van Vuuren, M., Howell, P. G., Groenewald, D. & Guthrie, A. J. (2008).** Molecular epidemiology of the African horse sickness virus S10 gene. *J Gen Virol* **89**, 1159-1168.
- Ramig, R. F., Garrison, C., Chen, D. & Bell-Robinson, D. (1989).** Analysis of reassortment and superinfection during mixed infection of Vero cells with bluetongue virus serotypes 10 and 17. *J Gen Virol* **70**, 2595-2603.
- Rodriguez-Sanchez, B., Fernandez-Pinero, J., Sailleau, C., Zientara, S., Belak, S., Arias, M. & Sanchez-Vizcaino, J. M. (2008).** Novel gel-based and real-time PCR assays for the improved detection of African horse sickness virus. *J Virol Methods* **151**, 87-94.
- Roner, M. R. & Mutsoli, C. (2007).** The use of monoreassortants and reverse genetics to map reovirus lysis of a ras-transformed cell line. *J Virol Methods* **139**, 132-142.
- Roy, P. (1996).** Orbivirus structure and assembly. *Virology* **216**, 1-11.
- Roy, P. (2008).** Functional mapping of bluetongue virus proteins and their interactions with host proteins during virus replication. *Cell Biochem Biophys* **50**, 143-157.
- Roy, P., Bishop, D. H., Howard, S., Aitchison, H. & Erasmus, B. (1996).** Recombinant baculovirus-synthesized African horsesickness virus (AHSV) outer-capsid protein VP2 provides protection against virulent AHSV challenge. *J Gen Virol* **77**, 2053-2057.
- Roy, P., Mertens, P. P. & Casal, I. (1994).** African horse sickness virus structure. *Comp Immunol Microbiol Infect Dis* **17**, 243-273.
- Ruiz, M. C., Diaz, Y., Pena, F., Aristimuno, O. C., Chemello, M. E. & Michelangeli, F. (2005).**  $\text{Ca}^{2+}$  permeability of the plasma membrane induced by rotavirus infection in cultured cells is inhibited by tunicamycin and brefeldin A. *Virology* **333**, 54-65.
- Sailleau, C., Moulay, S. & Zientara, S. (1997).** Nucleotide sequence comparison of the segments S10 of the nine African horsesickness virus serotypes. *Arch Virol* **142**, 965-978.
- Sambrook, J. & Russell, D. W. (2001).** *Molecular Cloning, a laboratory manual*. Cold Spring Harbour: Cold Spring Laboratory Press.
- Sánchez-Martínez, S., Huarte, N., Maeso, R., Madan, V., Carrasco, L. & Nieva, J. L. (2008).** Functional and structural characterization of 2B viroporin membranolytic domains. *Biochemistry* **47**, 10731-10739.
- Sanz, M. A., Madan, V., Carrasco, L. & Nieva, J. L. (2003).** Interfacial domains in sindbis virus 6K protein. *J Biol Chem* **278**, 2051-2057.
- Sanz, M. A., Perez, L. & Carrasco, L. (1994).** Semliki Forest virus 6 K protein modifies membrane permeability after inducible expression in *Escherichia coli* cells. *J Biol Chem* **269**, 12106-12110.
- Sapin, C., Colard, O., Delmas, O., Tessier, C., Breton, M., Enouf, V., Chwetzoff, S., Ouanich, J., Cohen, J., Wolf, C. & Trugnan, G. (2002).** Rafts promote assembly and atypical targeting of a nonenveloped virus, rotavirus, in Caco-2 cells. *J Virol* **76**, 4591-4602.
- Seo, N. S., Zeng, C. Q., Hyser, J. M., Utama, B., Crawford, S. E., Kim, K. J., Hook, M. & Estes, M. K. (2008).** Inaugural article: integrins alpha1beta1 and alpha2beta1 are receptors for the rotavirus enterotoxin. *Proc Natl Acad Sci U S A* **105**, 8811-8818.
- Silvestri, L. S., Tortorici, M. A., Vasquez-Del Carpio, R. & Patton, J. T. (2005).** Rotavirus glycoprotein NSP4 is a modulator of viral transcription in the infected cell. *J Virol* **79**, 15165-15174.

- Skowronek, A. J., LaFranco, L., Stone-Marschat, M. A., Burrage, T. G., Rebar, A. H. & Laegreid, W. W. (1995).** Clinical pathology and hemostatic abnormalities in experimental African horsesickness. *Vet Pathol* **32**, 112-121.
- Smit, C. C. (1999).** Identification of critical functional domains of nonstructural protein NS3 of African horsesickness virus. MSc Thesis. Pretoria: University of Pretoria.
- Stoltz, M. A., van der Merwe, C. F., Coetzee, J. & Huismans, H. (1996).** Subcellular localization of the nonstructural protein NS3 of African horsesickness virus. *Onderstepoort J Vet Res* **63**, 57-61.
- Stone-Marschat, M. A., Moss, S. R., Burrage, T. G., Barber, M. L., Roy, P. & Laegreid, W. W. (1996).** Immunization with VP2 is sufficient for protection against lethal challenge with African horsesickness virus Type 4. *Virology* **220**, 219-222.
- Storey, S. M., Gibbons, T. F., Williams, C. V., Parr, R. D., Schroeder, F. & Ball, J. M. (2007).** Full-Length, Glycosylated NSP4 is Localized to Plasma Membrane Caveolae by a Novel Raft Isolation Technique. *J Virol* **81**, 5472-5483.
- Studier, F. W. (1991).** Use of bacteriophage T7 lysozyme to improve an inducible T7 expression system. *J Mol Biol* **219**, 37-44.
- Studier, F. W. & Moffat, B. A. (1986).** Use of bacteriophage T7 RNA polymerase to direct selective high-level expression of cloned genes. *J Mol Biol* **189**, 113-130.
- Tauscher, G. I. & Desselberger, U. (1997).** Viral determinants of rotavirus pathogenicity in pigs: production of reassortants by asynchronous coinfection. *J Virol* **71**, 853-857.
- Taylor, J. A., O'Brien, J. A. & Yeager, M. (1996).** The cytoplasmic tail of NSP4, the endoplasmic reticulum-localized non-structural glycoprotein of rotavirus, contains distinct virus binding and coiled coil domains. *Embo J* **15**, 4469-4476.
- Teixeira, L. M. (2005).** The cytotoxicity of the nonstructural protein NS3 of equine encephalosis virus. MSc Thesis. Pretoria: University of Pretoria.
- Theiler, A. (1921).** African horsesickness. *Department of Agriculture Sci Bulletin* **19**, 1-32.
- Tian, P., Hu, Y., Schilling, W. P., Lindsay, D. A., Eiden, J. & Estes, M. K. (1994).** The nonstructural glycoprotein of rotavirus affects intracellular calcium levels. *J Virol* **68**, 251-257.
- Tini, M., Jewell, U. R., Camenisch, G., Chilov, D. & Gassmann, M. (2002).** Generation and application of chicken egg-yolk antibodies. *Comp Biochem Phys Part A* **131**, 569-574.
- Turnbull, P. J., Cormack, S. B. & Huismans, H. (1996).** Characterization of the gene encoding core protein VP6 of two African horsesickness virus serotypes. *J Gen Virol* **77** ( Pt 7), 1421-1423.
- Uitenweerde, J. M., Theron, J., Stoltz, M. A. & Huismans, H. (1995).** The multimeric nonstructural NS2 proteins of bluetongue virus, African horsesickness virus, and epizootic hemorrhagic disease virus differ in their single-stranded RNA-binding ability. *Virology* **209**, 624-632.
- Ulug, E. T., Garry, R. F. & Bose, H. R., Jr (1996).** Inhibition of Na<sup>+</sup>K<sup>+</sup>ATPase activity in membranes of Sindbis virus-infected chick cells. *Virology* **216**, 299-308.
- Van Dijk, A. A. & Huismans, H. (1988).** In vitro transcription and translation of bluetongue virus mRNA. *J Gen Virol* **69** 573-581.
- Van Kuppeveld, F. J. M., de Jong, A. S., Melchers, W. J. G. & Willems, P. H. G. M. (2005).** Enterovirus protein 2B po(u)res out the calcium: a viral strategy to survive? *Trends in Microbiology* **13**, 41-44.
- Van Niekerk, M. (2001).** Association of nonstructural protein NS3 of African horsesickness virus with cytotoxicity and virus virulence. PhD Thesis. Pretoria: University of Pretoria.
- Van Niekerk, M., Freeman, M., Paweska, J. T., Howell, P. G., Guthrie, A. J., Potgieter, A. C., van Staden, V. & Huismans, H. (2003).** Variation in the NS3 gene and protein in South African isolates of bluetongue and equine encephalosis viruses. *J Gen Virol* **84**, 581-590.
- Van Niekerk, M., Smit, C. C., Fick, W. C., van Staden, V. & Huismans, H. (2001a).** Membrane association of African horsesickness virus nonstructural protein NS3 determines its cytotoxicity. *Virology* **279**, 499-508.
- Van Niekerk, M., van Staden, V., van Dijk, A. A. & Huismans, H. (2001b).** Variation of African horsesickness virus nonstructural protein NS3 in southern Africa. *J Gen Virol* **82**, 149-158.
- Van Staden, V. & Huismans, H. (1991).** A comparison of the genes which encode non-structural protein NS3 of different orbiviruses. *J Gen Virol* **72**, 1073-1079.
- Van Staden, V., Smit, C. C., Stoltz, M. A., Maree, F. F. & Huismans, H. (1998).** Characterization of two African horse sickness virus non-structural proteins, NS1 and NS3. *Arch Virol Suppl* **14**, 251-258.
- Van Staden, V., Stoltz, M. A. & Huismans, H. (1995).** Expression of nonstructural protein NS3 of African horsesickness virus (AHSV): evidence for a cytotoxic effect of NS3 in insect cells, and characterization of the gene products in AHSV infected Vero cells. *Arch Virol* **140**, 289-306.
- Venter, G. J., Graham, S. D. & Hamblin, C. (2000).** African horse sickness epidemiology: vector competence of south african Culicoides species for virus serotypes 3, 5 and 8. *Med Vet Entomol* **14**, 245-250.
- Von Heijne, G. (1996).** Principles of membrane protein assembly and structure. *Prog Biophys Mol Biol* **66**, 113-139.

- Von Teichman, B. F. & Smit, T. K. (2008).** Evaluation of the pathogenicity of African Horsesickness (AHS) isolates in vaccinated animals. *Vaccine* **26**, 5014-5021.
- Watanabe, T., Watanabe, S., Ito, H., Kida, H. & Kawaoka, Y. (2001).** Influenza A virus can undergo multiple cycles of replication without M2 ion channel activity. *J Virol* **75**, 5656–5662.
- Wirblich, C., Bhattacharya, B. & Roy, P. (2006).** Nonstructural protein 3 of bluetongue virus assists virus release by recruiting ESCRT-I protein Tsg101. *J Virol* **80**, 460-473.
- Wohlsein, P., Pohlenz, J. F., Davidson, F. L., Salt, J. S. & Hamblin, C. (1997).** Immunohistochemical demonstration of African horse sickness viral antigen in formalin-fixed equine tissues. *Vet Pathol* **34**, 568-574.
- Wu, X., Chen, S. Y., Iwata, H., Compans, R. W. & Roy, P. (1992).** Multiple glycoproteins synthesized by the smallest RNA segment (S10) of bluetongue virus. *J Virol* **66**, 7104-7112.
- Xu, A., Bellamy, A. R. & Taylor, J. A. (1998).** BiP (GRP78) and endoplasmic reticulum-localized virion component. *J Virol* **72**, 9865-9872.
- Xu, A., Bellamy, A. R. & Taylor, J. A. (2000).** Immobilization of the early secretory pathway by a virus glycoprotein that binds to microtubules. *Embo J* **19**, 6465-6474.
- Zambrano, J. L., Diaz, Y., Pena, F., Vizzi, E., Ruiz, M. C., Michelangeli, F., Liprandi, F. & Ludert, J. E. (2008).** Silencing of rotavirus NSP4 or VP7 expression reduces alterations in  $\text{Ca}^{2+}$  homeostasis induced by infection of cultured cells. *J Virol* **82**, 5815-5824.
- Zhang, M., Zeng, C. Q., Dong, Y., Ball, J. M., Saif, L. J., Morris, A. P. & Estes, M. K. (1998).** Mutations in rotavirus nonstructural glycoprotein NSP4 are associated with altered virus virulence. *J Virol* **72**, 3666-3672.
- Zhang, M., Zeng, C. Q., Morris, A. P. & Estes, M. K. (2000).** A functional NSP4 enterotoxin peptide secreted from rotavirus-infected cells. *J Virol* **74**, 11663-11670.

## APPENDIX A

### Nucleotide sequence alignments of reassortant virus genome segments

#### VP2 gene (Segment 2)

		1	50
AHSV-3	(1)	TGTGCAATGATTACCGAATGAGACGCGAGAGAGCACGCTCAAGGGAT	
AHSV-4	(1)	TATATGAGG-TTATACGATGTGAGACAAGGGAGCAGGCACATAAAATACCT	
R4-2 <sub>4,5,7,10</sub>	(1)	TATATGAGG-TTATACGATGTGAGACAAGGGAGCAGGCACATAAAATACCT	
R4-2 <sub>7,10</sub>	(1)	TATATGAGG-TTATACGATGTGAGACAAGGGAGCAGGCACATAAAATACCT	
R4-2 <sub>10</sub>	(1)	TATATGAGG-TTATACGATGTGAGACAAGGGAGCAGGCACATAAAATACCT	
R3-2 <sub>5,10</sub>	(1)	TGTGCAATGATTACCGAATGAGACGCGAGAGAGCACGCTCAAGGGAT	
R3-2 <sub>3,5</sub>	(1)	TGTGCAATGATTACCGAATGAGACGCGAGAGAGCACGCTCAAGGGAT	
		51	100
AHSV-3	(50)	TTA-GTATGTTACTGCAATTGTTAAAAGTGAGGAGACTGATAGATACCT	
AHSV-4	(50)	TCA <sup>C</sup> GGATTTCACAGGTGT-GTTGAGTCGGAACTGCTTTTACCGACACT	
R4-2 <sub>4,5,7,10</sub>	(50)	TCA <sup>C</sup> GGATTTCACAGGTGT-GTTGAGTCGGAACTGCTTTTACCGACACT	
R4-2 <sub>7,10</sub>	(50)	TCA <sup>C</sup> GGATTTCACAGGTGT-GTTGAGTCGGAACTGCTTTTACCGACACT	
R4-2 <sub>10</sub>	(50)	TCA <sup>C</sup> GGATTTCACAGGTGT-GTTGAGTCGGAACTGCTTTTACCGACACT	
R3-2 <sub>5,10</sub>	(50)	TTA-GTATGTTACTGCAATTGTTAAAAGTGAGGAGACTGATAGATACCT	
R3-2 <sub>3,5</sub>	(50)	TTA-GTATGTTACTGCAATTGTTAAAAGTGAGGAGACTGATAGATACCT	
		101	150
AHSV-3	(99)	GTTCTTGAATTTCCTGTTATGGATTGCTTGAATGGA <sup>G</sup> AATGTTGATG	
AHSV-4	(99)	TAAACTTAACCTTCGCTGTGGATTGCTTGAATGGA <sup>A</sup> AAACGTTGAAG	
R4-2 <sub>4,5,7,10</sub>	(99)	TAAACTTAACCTTCGCTGTGGATTGCTTGAATGGA <sup>A</sup> AAACGTTGAAG	
R4-2 <sub>7,10</sub>	(99)	TAAACTTAACCTTCGCTGTGGATTGCTTGAATGGA <sup>A</sup> AAACGTTGAAG	
R4-2 <sub>10</sub>	(99)	TAAACTTAACCTTCGCTGTGGATTGCTTGAATGGA <sup>A</sup> AAACGTTGAAG	
R3-2 <sub>5,10</sub>	(99)	GTTCTTGAATTTCCTGTTATGGATTGCTTGAATGGA <sup>G</sup> AATGTTGATG	
R3-2 <sub>3,5</sub>	(99)	GTTCTTGAATTTCCTGTTATGGATTGCTTGAATGGA <sup>G</sup> AATGTTGATG	
		151	200
AHSV-3	(149)	TGAGCGCTGCTAAATAAGAGACATCCATTATTAATATCGCATGAAAAAGGA	
AHSV-4	(149)	TGAACCGGGCGTACAAGCGTCATCCGCTTTAATCTCAACTGCCAAAGGG	
R4-2 <sub>4,5,7,10</sub>	(149)	TGAACCGGGCGTACAAGCGTCATCCGCTTTAATCTCAACTGCCAAAGGG	
R4-2 <sub>7,10</sub>	(149)	TGAACCGGGCGTACAAGCGTCATCCGCTTTAATCTCAACTGCCAAAGGG	
R4-2 <sub>10</sub>	(149)	TGAACCGGGCGTACAAGCGTCATCCGCTTTAATCTCAACTGCCAAAGGG	
R3-2 <sub>5,10</sub>	(149)	TGAGCGCTGCTAAATAAGAGACATCCATTATTAATATCGCATGAAAAAGGA	
R3-2 <sub>3,5</sub>	(149)	TGAGCGCTGCTAAATAAGAGACATCCATTATTAATATCGCATGAAAAAGGA	
		201	250
AHSV-3	(199)	TTACGTTTAATTGGCGTAGATTGTTAATGGCGCGCTTCGATTCAC	
AHSV-4	(199)	TTAAGGGTTATCGCGGTGATATTTCAACTCACAGCTTCGATATCAAT	
R4-2 <sub>4,5,7,10</sub>	(199)	TTAAGGGTTATCGCGGTGATATTTCAACTCACAGCTTCGATATCAAT	
R4-2 <sub>7,10</sub>	(199)	TTAAGGGTTATCGCGGTGATATTTCAACTCACAGCTTCGATATCAAT	
R4-2 <sub>10</sub>	(199)	TTAAGGGTTATCGCGGTGATATTTCAACTCACAGCTTCGATATCAAT	
R3-2 <sub>5,10</sub>	(199)	TTACGTTTAATTGGCGTAGATTGTTAATGGCGCGCTTCGATTCAC	
R3-2 <sub>3,5</sub>	(199)	TTACGTTTAATTGGCGTAGATTGTTAATGGCGCGCTTCGATTCAC	
		251	300
AHSV-3	(249)	GGGGGGGTGGATTCCGTATCTAGAGAGGGATATGTCAGAGGAGAAAGCTC	
AHSV-4	(249)	GAGCGGATGGATTCCGTATGTCGAACGGATGTGCCCGGAGAGTAAAGTC	
R4-2 <sub>4,5,7,10</sub>	(249)	GAGCGGATGGATTCCGTATGTCGAACGGATGTGCCCGGAGAGTAAAGTC	
R4-2 <sub>7,10</sub>	(249)	GAGCGGATGGATTCCGTATGTCGAACGGATGTGCCCGGAGAGTAAAGTC	
R4-2 <sub>10</sub>	(249)	GAGCGGATGGATTCCGTATGTCGAACGGATGTGCCCGGAGAGTAAAGTC	
R3-2 <sub>5,10</sub>	(249)	GGGGGGGTGGATTCCGTATCTAGAGAGGGATATGTCAGAGGAGAAAGCTC	
R3-2 <sub>3,5</sub>	(249)	GGGGGGGTGGATTCCGTATCTAGAGAGGGATATGTCAGAGGAGAAAGCTC	
		301	
AHSV-3	(299)	AGA-GAAGG	
AHSV-4	(299)	AAA <sup>C</sup> GAAGT	
R4-2 <sub>4,5,7,10</sub>	(299)	AAA <sup>C</sup> GAAGT	
R4-2 <sub>7,10</sub>	(299)	AAA <sup>C</sup> GAAGT	
R4-2 <sub>10</sub>	(299)	AAA <sup>C</sup> GAAGT	
R3-2 <sub>5,10</sub>	(299)	AGA-GAAGG	
R3-2 <sub>3,5</sub>	(299)	AGA-GAAGG	

### VP3 gene (Segment 3)

	1	50
AHSV-2	(1) ATTTAAAAGCAACCATTCTCACTCCATCCCTCTCCTCTTC	TGTGTACACA
AHSV-3	(1) ATTTAAAAGCGACCATCCTCACTCCATCCCTCTCCTCTCGTGTACACA	
AHSV-4	(1) ATTTAAAAGCGACCATTCTCACTCCATCCCTCTCCTCTCGTGTACACA	
R4-2 <sub>4,5,7,10</sub>	(1) ATTTAAAAGCGACCATTCTCACTCCATCCCTCTCCTCTCGTGTACACA	
R4-2 <sub>7,10</sub>	(1) ATTTAAAAGCGACCATTCTCACTCCATCCCTCTCCTCTCGTGTACACA	
R4-2 <sub>10</sub>	(1) ATTTAAAAGCGACCATTCTCACTCCATCCCTCTCCTCTCGTGTACACA	
R3-2 <sub>5,10</sub>	(1) ATTTAAAAGCGACCATCCTCACTCCATCCCTCTCCTCTCGTGTACACA	
R3-2 <sub>3,5</sub>	(1) ATTTAAAAGCAACCATTCTCACTCCATCCCTCTCCTCTCGTGTACACA	
	51	100
AHSV-2	(51) TAAGGCATTGCCGTCAAGTATCTCGTCGGGCGGCCGTGAATCAAAGAATT	
AHSV-3	(51) TAAGGCATTGCCGTCAAGTATCTCGTCGGGCGGCCGTGAATCAAAAGAATT	
AHSV-4	(51) TAAGGCATTGCCGTCAAGTATCTCGTCGGGCGGCCGTGAATCAAAAGAATT	
R4-2 <sub>4,5,7,10</sub>	(51) TAAGGCATTGCCGTCAAGTATCTCGTCGGGCGGCCGTGAATCAAAAGAATT	
R4-2 <sub>7,10</sub>	(51) TAAGGCATTGCCGTCAAGTATCTCGTCGGGCGGCCGTGAATCAAAAGAATT	
R4-2 <sub>10</sub>	(51) TAAGGCATTGCCGTCAAGTATCTCGTCGGGCGGCCGTGAATCAAAAGAATT	
R3-2 <sub>5,10</sub>	(51) TAAGGCATTGCCGTCAAGTATCTCGTCGGGCGGCCGTGAATCAAAAGAATT	
R3-2 <sub>3,5</sub>	(51) TAAGGCATTGCCGTCAAGTATCTCGTCGGGCGGCCGTGAATCAAAAGAATT	
	101	127
AHSV-2	(101) AATCTTGATGTTCCGTAACATACCAACC	
AHSV-3	(101) AATCTTGATATTCCGTAACATACCAACC	
AHSV-4	(101) AATCTTGATATTCCGTAACATACCAACC	
R4-2 <sub>4,5,7,10</sub>	(101) AATCTTGATATTCCGTAACATACCAACC	
R4-2 <sub>7,10</sub>	(101) AATCTTGATATTCCGTAACATACCAACC	
R4-2 <sub>10</sub>	(101) AATCTTGATATTCCGTAACATACCAACC	
R3-2 <sub>5,10</sub>	(101) AATCTTGATATTCCGTAACATACCAACC	
R3-2 <sub>3,5</sub>	(101) AATCTTGATGTTCCGTAACATACCAACC	

### NS1 gene (segment 5)

	1	50
AHSV-2	(1) CCAGTGGTTGATTCAAAAAT	TGCTGAACTAACGGGAGGCACAGATGTATT
AHSV-3	(1) CCAGTGGTTGATTCAAAAAT	TGCTGAACTAACAGGAGGCATAGATGTATT
AHSV-4	(1) CCAGTGGTTGATTCAAAAAT	CGCTGAACTAACAGGAGGCACGGATGTATT
R4-2 <sub>4,5,7,10</sub>	(1) CCAGTGGTTGATTCAAAAAT	TGCTGAACTAACGGGAGGCACAGATGTATT
R4-2 <sub>7,10</sub>	(1) CCAGTGGTTGATTCAAAAAT	CGCTGAACTAACAGGAGGCACGGATGTATT
R4-2 <sub>10</sub>	(1) CCAGTGGTTGATTCAAAAAT	CGCTGAACTAACAGGAGGCACGGATGTATT
R3-2 <sub>5,10</sub>	(1) CCAGTGGTTGATTCAAAAAT	TGCTGAACTAACGGGAGGCACAGATGTATT
R3-2 <sub>3,5</sub>	(1) CCAGTGGTTGATTCAAAAAT	TGCTGAACTAACGGGAGGCACAGATGTATT
	51	100
AHSV-2	(51) TTATACACGTGCGTATGTACATGCGGACAATCACAAAG	CGCCAAATGTCA
AHSV-3	(51) TTATACACGTGCGTATGTACATGCGGACAATCACAAAGTGCCAAATGTCA	
AHSV-4	(51) TTATACACGTGCGTATGTACATGCGGACAATCACAAAGTGCCAAATGTCA	
R4-2 <sub>4,5,7,10</sub>	(51) TTATACACGTGCGTATGTACATGCGGACAATCACAAAG	CGCCAAATGTCA
R4-2 <sub>7,10</sub>	(51) TTATACACGTGCGTATGTACATGCGGACAATCACAAAGTGCCAAATGTCA	
R4-2 <sub>10</sub>	(51) TTATACACGTGCGTATGTACATGCGGACAATCACAAAGTGCCAAATGTCA	
R3-2 <sub>5,10</sub>	(51) TTATACACGTGCGTATGTACATGCGGACAATCACAAAG	CGCCAAATGTCA
R3-2 <sub>3,5</sub>	(51) TTATACACGTGCGTATGTACATGCGGACAATCACAAAGCGCCAAATGTCA	
	101	150
AHSV-2	(101) GAGATTGATGATGAATGAAGTCTTCAGGAAGATT	GATGATCATTGGGTG
AHSV-3	(101) GAGATTGATGATGAATGAAGTCTTCAGGAAGATTGATGATCATTGGGTG	
AHSV-4	(101) GAGATTGATGATGAATGAAGTCTTCAGGAAGATTGATGATCATTGGGTG	
R4-2 <sub>4,5,7,10</sub>	(101) GAGATTGATGATGAATGAAGTCTTCAGGAAGATTGATGATCATTGGGTG	
R4-2 <sub>7,10</sub>	(101) GAGATTGATGATGAATGAAGTCTTCAGGAAGATTGATGATCATTGGGTG	
R4-2 <sub>10</sub>	(101) GAGATTGATGATGAATGAAGTCTTCAGGAAGATTGATGATCATTGGGTG	
R3-2 <sub>5,10</sub>	(101) GAGATTGATGATGAATGAAGTCTTCAGGAAGATTGATGATCATTGGGTG	
R3-2 <sub>3,5</sub>	(101) GAGATTGATGATGAATGAAGTCTTCAGGAAGATTGATGATCATTGGGTG	
	151	200
AHSV-2	(151) ATTCAGAAAGTGTCATAC	ACCGAAGGAAGCGATTACCGTAACTGCAATTCA
AHSV-3	(151) ATTCAGAAAGTGTCATAC	ACCGAAGGAAGCGATTACCGTAACTGCAATTCA
AHSV-4	(151) ATTCAGAAAGTGTCATACCACCGAAGGAAGCGATTACTGTAACTGCAATTCA	
R4-2 <sub>4,5,7,10</sub>	(151) ATTCAGAAAGTGTCATAC	ACCGAAGGAAGCGATTACCGTAACTGCAATTCA
R4-2 <sub>7,10</sub>	(151) ATTCAGAAAGTGTCATACCACCGAAGGAAGCGATTACTGTAACTGCAATTCA	
R4-2 <sub>10</sub>	(151) ATTCAGAAAGTGTCATACCACCGAAGGAAGCGATTACTGTAACTGCAATTCA	
R3-2 <sub>5,10</sub>	(151) ATTCAGAAAGTGTCATAC	ACCGAAGGAAGCGATTACCGTAACTGCAATTCA
R3-2 <sub>3,5</sub>	(151) ATTCAGAAAGTGTCATAC	ACCGAAGGAAGCGATTACCGTAACTGCAATTCA
	201	250
AHSV-2	(201) AATCCAGAGGTCGATCAGAGGTGATGGACAGTGGGATACTCCGATGTTTC	
AHSV-3	(201) GATCCAGAGGTCGATCAGAGGTGATGGGACAGTGGGATACTCCGATGTTTC	
AHSV-4	(201) GATTCAGAGGTCGATCAGAGGTGATGGGACAGTGGGATACTCCGATGTTTC	
R4-2 <sub>4,5,7,10</sub>	(201) AATCCAGAGGTCGATCAGAGGTGATGGACAGTGGGATACTCCGATGTTTC	
R4-2 <sub>7,10</sub>	(201) GATTCAGAGGTCGATCAGAGGTGATGGGACAGTGGGATACTCCGATGTTTC	
R4-2 <sub>10</sub>	(201) GATTCAGAGGTCGATCAGAGGTGATGGGACAGTGGGATACTCCGATGTTTC	
R3-2 <sub>5,10</sub>	(201) AATCCAGAGGTCGATCAGAGGTGATGGACAGTGGGATACTCCGATGTTTC	
R3-2 <sub>3,5</sub>	(201) AATCCAGAGGTCGATCAGAGGTGATGGACAGTGGGATACTCCGATGTTTC	
	251	300
AHSV-2	(251) ACCAATCAATGGCTCTGTT	GACACGATTGATTGTTATTGGTTAACGGAT
AHSV-3	(251) ACCAATCAATGGCTCTGTTAACACGATTGATTGTTATTGGTTAACGGAT	
AHSV-4	(251) ACCAATCAATGGCTCTGTTAACACGATTGATTGTTATTGGTTAACGGAT	
R4-2 <sub>4,5,7,10</sub>	(251) ACCAATCAATGGCTCTGTT	GACACGATTGATTGTTATTGGTTAACGGAT
R4-2 <sub>7,10</sub>	(251) ACCAATCAATGGCTCTGTTAACACGATTGATTGTTATTGGTTAACGGAT	
R4-2 <sub>10</sub>	(251) ACCAATCAATGGCTCTGTTAACACGATTGATTGTTATTGGTTAACGGAT	
R3-2 <sub>5,10</sub>	(251) ACCAATCAATGGCTCTGTT	GACACGATTGATTGTTATTGGTTAACGGAT
R3-2 <sub>3,5</sub>	(251) ACCAATCAATGGCTCTGTT	GACACGATTGATTGTTATTGGTTAACGGAT

	301	350
AHSV-2	(301) GTGACTGAGAGAACGCTATCTTCGGCTGACTTGTTCGCAATCTTCGG	
AHSV-3	(301) GTGACTGAGAGAACGCTATCTTCGGCTGACTTGTTCGCAATCTTCGG	
AHSV-4	(301) GTGACTGAGAGAACGCTATCTTCGGCTGACTTGTTCGCAATCTTCGG	
R4-2 <sub>4,5,7,10</sub>	(301) GTGACTGAGAGAACGCTATCTTCGGCTGACTTGTTCGCAATCTTCGG	
R4-2 <sub>7,10</sub>	(301) GTGACTGAGAGAACGCTATCTTCGGCTGACTTGTTCGCGATCTTCGG	
R4-2 <sub>10</sub>	(301) GTGACTGAGAGAACGCTATCTTCGGCTGACTTGTTCGCGATCTTCGG	
R3-2 <sub>5,10</sub>	(301) GTGACTGAGAGAACGCTATCTTCGGCTGACTTGTTCGCAATCTTCGG	
R3-2 <sub>3,5</sub>	(301) GTGACTGAGAGAACGCTATCTTCGGCTGACTTGTTCGCAATCTTCGG	
	351	399
AHSV-2	(351) ATGTAAGCCAACAGCTCGAGGTAGATATATTGAATGGGACGATCTTGG	
AHSV-3	(351) ATGTAAGCCAACAGCTCGAGGTAGATATATTGACTGGGATGATCTTGG	
AHSV-4	(351) ATGTAAGCCGACGGCTCGAGGTAGATATATTGAATGGGATGATCTTGG	
R4-2 <sub>4,5,7,10</sub>	(351) ATGTAAGCCAACAGCTCGAGGTAGATATATTGAATGGGACGATCTTGG	
R4-2 <sub>7,10</sub>	(351) ATGTAAGCCGACGGCTCGAGGTAGATATATTGAATGGGATGATCTTGG	
R4-2 <sub>10</sub>	(351) ATGTAAGCCGACGGCTCGAGGTAGATATATTGAATGGGATGATCTTGG	
R3-2 <sub>5,10</sub>	(351) ATGTAAGCCAACAGCTCGAGGTAGATATATTGAATGGGACGATCTTGG	
R3-2 <sub>3,5</sub>	(351) ATGTAAGCCAACAGCTCGAGGTAGATATATTGAATGGGACGATCTTGG	

### VP5 gene (Segment 6)

	1	50
AHSV-3	(1) TGAAGAAGCTGTGCAGGAGATGTTGGATTAAAGTGCAGGGTCATCGAAA	
AHSV-4	(1) TGATGAAGCGATTCAAGGAGATGCTCGACTTAAGCGCAGAACGATTGAGA	
R4-2 <sub>4,5,7,10</sub>	(1) TGATGAAGCGATTCAAGGAGATGCTCGACTTAAGCGCAGAACGATTGAGA	
R4-2 <sub>7,10</sub>	(1) TGATGAAGCGATTCAAGGAGATGCTCGACTTAAGCGCAGAACGATTGAGA	
R4-2 <sub>10</sub>	(1) TGATGAAGCGATTCAAGGAGATGCTCGACTTAAGCGCAGAACGATTGAGA	
R3-2 <sub>5,10</sub>	(1) TGAAGAAGCTGTGCAGGAGATGTTGGATTAAAGTGCAGGGTCATCGAAA	
R3-2 <sub>3,5</sub>	(1) TGAAGAAGCTGTGCAGGAGATGTTGGATTAAAGTGCAGGGTCATCGAAA	
	51	100
AHSV-3	(51) CGGCGGCTGAGGAGGTGCCAATCTTGGCGCAGGGCAGCAAATGTTGTT	
AHSV-4	(51) CTGCGTCGGAGGAGGTACCAATTGGGGCGCAGAACGTTATC	
R4-2 <sub>4,5,7,10</sub>	(51) CTGCGTCGGAGGAGGTACCAATTGGGGCGCAGAACGTTATC	
R4-2 <sub>7,10</sub>	(51) CTGCGTCGGAGGAGGTACCAATTGGGGCGCAGAACGTTATC	
R4-2 <sub>10</sub>	(51) CTGCGTCGGAGGAGGTACCAATTGGGGCGCAGAACGTTATC	
R3-2 <sub>5,10</sub>	(51) CGGCGGCTGAGGAGGTGCCAATCTTGGCGCAGGGCAGCAAATGTTGTT	
R3-2 <sub>3,5</sub>	(51) CGGCGGCTGAGGAGGTGCCAATCTTGGCGCAGGGCAGCAAATGTTGTT	
	101	150
AHSV-3	(101) GCGACGACACGCGCAATCCAAGGGGTTCTAAAGTGAAGGAGATAATAGA	
AHSV-4	(101) GCCACAACCGAGCAATACAGGGGGGTTAAAACAAAGGAAATTGTGGA	
R4-2 <sub>4,5,7,10</sub>	(101) GCCACAACCGAGCAATACAGGGGGGTTAAAACAAAGGAAATTGTGGA	
R4-2 <sub>7,10</sub>	(101) GCCACAACCCGAGCAATACAGGGGGGTTAAAACAAAGGAAATTGTGGA	
R4-2 <sub>10</sub>	(101) GCCACAACCCGAGCAATACAGGGGGGTTAAAACAAAGGAAATTGTGGA	
R3-2 <sub>5,10</sub>	(101) GCGACGACACGCGCAATCCAAGGGGTTCTAAAGTGAAGGAGATAATAGA	
R3-2 <sub>3,5</sub>	(101) GCGACGACACGCGCAATCCAAGGGGTTCTAAAGTGAAGGAGATAATAGA	
	151	185
AHSV-3	(151) TAAACTCACAGGATTGATCTCTCTCATTTGAAAG	
AHSV-4	(151) TAAGCTTACGGGAATAGACTTGAGTCATTGAAAGG	
R4-2 <sub>4,5,7,10</sub>	(151) TAAGCTTACGGGAATAGACTTGAGTCATTGAAAGG	
R4-2 <sub>7,10</sub>	(151) TAAGCTTACGGGAATAGACTTGAGTCATTGAAAGG	
R4-2 <sub>10</sub>	(151) TAAGCTTACGGGAATAGACTTGAGTCATTGAAAGG	
R3-2 <sub>5,10</sub>	(151) TAAACTCACAGGATTGATCTCTCTCATTTGAAAG	
R3-2 <sub>3,5</sub>	(151) TAAACTCACAGGATTGATCTCTCTCATTTGAAAG	

### VP7 gene (Segment 7)

		1	50
AHSV-2	(1)	GGACCAAGTAAAGTCAGACGGGACCTATGCAGGAGCGGCTGAGGTGCA	
AHSV-3	(1)	GGACCAAGCAAAGTACAGACGGGACCTATGCAGGAGCAGTTGAGGTGCA	
AHSV-4	(1)	GGACCAAGCAAAGTCAACGGGACCTATGCAGGAGCGGTAGAGGTGCA	
R4-2 <sub>4,5,7,10</sub>	(1)	GGACCAAGTAAAGTCAGACGGGACCTATGCAGGAGCGGCTGAGGTGCA	
R3-2 <sub>5,10</sub>	(1)	GGACCAAGCAAAGTACAGACGGGACCTATGCAGGAGCAGTTGAGGTGCA	
R3-2 <sub>3,5</sub>	(1)	GGACCAAGCAAAGTACAGACGGGACCTATGCAGGAGCAGTTGAGGTGCA	
		51	100
AHSV-2	(51)	ACAGTCTGGCAGATATTATGACCGAAGGTCGAACACGTGGTGGTACA	
AHSV-3	(51)	ACAATCTGGCAGATATTACGTACCGAAGGTCGAACACGTGGTGGTACA	
AHSV-4	(51)	ACAATCTGGCAGATATTACGTACCGAAGGTCGAACACGTGGTGGTACA	
R4-2 <sub>4,5,7,10</sub>	(51)	ACAGTCTGGCAGATATTATGACCGAAGGTCGAACACGTGGTGGTACA	
R3-2 <sub>5,10</sub>	(51)	ACAATCTGGCAGATATTACGTACCGAAGGTCGAACACGTGGTGGTACA	
R3-2 <sub>3,5</sub>	(51)	ACAATCTGGCAGATATTACGTACCGAAGGTCGAACACGTGGTGGTACA	
		101	150
AHSV-2	(101)	TCAATTCAAATATTGCTGAAGTGTGTATGGATGCGGGTGCTCGGGACAG	
AHSV-3	(101)	TTAATTCAAATATTGCTGAAGTGTGTATGGATGCAAGCGCTGCAGGACAG	
AHSV-4	(101)	TCAATTCAAATATTGCTGAGGTGTATGGATGCAAGGTGCTGCAGGACAG	
R4-2 <sub>4,5,7,10</sub>	(101)	TCAATTCAAATATTGCTGAAGTGTGTATGGATGCGGGTGCTGCAGGACAG	
R3-2 <sub>5,10</sub>	(101)	TTAATTCAAATATTGCTGAAGTGTGTATGGATGCAAGCGCTGCAGGACAG	
R3-2 <sub>3,5</sub>	(101)	TTAATTCAAATATTGCTGAAGTGTGTATGGATGCAAGCGCTGCAGGACAG	
		151	200
AHSV-2	(151)	GTCAATGCGCTGCTAGCCCCAACGGAGGGGGACGCAGTCATGATCTATT	
AHSV-3	(151)	GTCAATGCGCTGCTAGCCCCAACGGAGGGGGACGCAGTCATGATCTATT	
AHSV-4	(151)	GTCAATGCGCTGCTAGCCCCAACGGAGGGGGACGCAGTCATGATCTATT	
R4-2 <sub>4,5,7,10</sub>	(151)	GTCAATGCGCTGCTAGCCCCAACGGAGGGGGACGCAGTCATGATCTATT	
R3-2 <sub>5,10</sub>	(151)	GTCAATGCGCTGCTAGCCCCAACGGAGGGGGACGCAGTCATGATCTATT	
R3-2 <sub>3,5</sub>	(151)	GTCAATGCGCTGCTAGCCCCAACGGAGGGGGACGCAGTCATGATCTATT	
		201	250
AHSV-2	(201)	CGTTTGGAGACCGCTGCGTATATTCTGTGATCCTCAAGGTGCATCACTCG	
AHSV-3	(201)	TGTTTGGAGACCATTGCCTATATTCTGTGATCCTCAAGGTGCCTCAACTTG	
AHSV-4	(201)	CGTTTGGAGGCCGTGCGTATATTCTGTGATCCTCAAGGTGCCTCAACTTG	
R4-2 <sub>4,5,7,10</sub>	(201)	CGTTTGGAGACCGCTGCGTATATTCTGTGATCCTCAAGGTGCATCACTCG	
R3-2 <sub>5,10</sub>	(201)	TGTTTGGAGACCATTGCCTATATTCTGTGATCCTCAAGGTGCCTCAACTTG	
R3-2 <sub>3,5</sub>	(201)	TGTTTGGAGACCATTGCCTATATTCTGTGATCCTCAAGGTGCCTCAACTTG	
		251	
AHSV-2	(251)	AGAGCGCTCC	
AHSV-3	(251)	AAAGCGCTCC	
AHSV-4	(251)	AGAGCGCTCC	
R4-2 <sub>4,5,7,10</sub>	(251)	AGAGCGCTCC	
R3-2 <sub>5,10</sub>	(251)	AAAGCGCTCC	
R3-2 <sub>3,5</sub>	(251)	AAAGCGCTCC	

## NS2 gene (Segment 8)

	1	50
AHSV-2	(1) AGCTTAATGATTACTGAGAGTGGATTGAGGTAAACGCAAAACCGATGGGA	
AHSV-3	(1) AGCTTAATGATTACTGAGAGTGGATTGAGGTAAACGCAAAACCGATGGGA	
AHSV-4	(1) AGCTTAATGATTACTGAAAGTGGATTGAGGTGACGCAAAACCGATGGGA	
R4-2 <sub>4,5,7,10</sub>	(1) AGTTTAATGATTACTGAAAGTGGATTGAGGTGACGCAAAACCGATGGGA	
R4-2 <sub>7,10</sub>	(1) AGTTTAATGATTACTGAAAGTGGATTGAGGTGACGCAAAACCGATGGGA	
R4-2 <sub>10</sub>	(1) AGTTTAATGATTACTGAAAGTGGATTGAGGTGACGCAAAACCGATGGGA	
R3-2 <sub>5,10</sub>	(1) AGTTTAATGATTACTGAGAGTGGATTGAGGTAAACGCAAAACCGATGGGA	
R3-2 <sub>3,5</sub>	(1) AGTTTAATGATTACTGAGAGTGGATTGAGGTAAACGCAAAACCGATGGGA	
	51	100
AHSV-2	(51) GGAGTGGAGCTTTGAGCGCTAACACCAGTACCGATGGCTGTGGCGGTGA	
AHSV-3	(51) GGAGTGGAGCTTTGAGCGCTAACACCAGTACCAATGGCAGTGGCGGTGA	
AHSV-4	(51) AGAGTGGAGCTTTGAGCGCTAACACCAGTACCAATGGCTGTGGCGGTCA	
R4-2 <sub>4,5,7,10</sub>	(51) AGAGTGGAGCTTTGAGCGCTAACACCAGTACCAATGGCTGTGGCGGTCA	
R4-2 <sub>7,10</sub>	(51) AGAGTGGAGCTTTGAGCGCTAACACCAGTACCAATGGCTGTGGCGGTCA	
R4-2 <sub>10</sub>	(51) AGAGTGGAGCTTTGAGCGCTAACACCAGTACCAATGGCTGTGGCGGTCA	
R3-2 <sub>5,10</sub>	(51) GGAGTGGAGCTTTGAGCGCTAACACCAGTACCAATGGCAGTGGCGGTGA	
R3-2 <sub>3,5</sub>	(51) GGAGTGGAGCTTTGAGCGCTAACACCAGTACCAATGGCAGTGGCGGTGA	
	101	150
AHSV-2	(101) ATGTAGGGAGAGGCTCGTTGACACTGAGATTAATATGTGAGAGGAAGC	
AHSV-3	(101) ATGTAGGGAGAGGCTCGTTGACACTGAGATTAATATGTGAGAGGAAGC	
AHSV-4	(101) ACGTAGGGAGAGGCTCGTTGACACTGAGATTAATATGTGAGAGGAAGC	
R4-2 <sub>4,5,7,10</sub>	(101) ACGTAGGGAGAGGCTCGTTGACACTGAGATTAATATGTGAGAGGAAGC	
R4-2 <sub>7,10</sub>	(101) ACGTAGGGAGAGGCTCGTTGACACTGAGATTAATATGTGAGAGGAAGC	
R4-2 <sub>10</sub>	(101) ACGTAGGGAGAGGCTCGTTGACACTGAGATTAATATGTGAGAGGAAGC	
R3-2 <sub>5,10</sub>	(101) ATGTAGGGAGAGGCTCGTTGACACTGAGATTAATATGTGAGAGGAAGC	
R3-2 <sub>3,5</sub>	(101) ATGTAGGGAGAGGCTCGTTGACACTGAGATTAATATGTGAGAGGAAGC	
	151	200
AHSV-2	(151) GGTGCAGTTCCACCTTATACGAAGAATGGAATGGATCGAAGAGCGATGCC	
AHSV-3	(151) GGTGCAGTTCCACCTTATACGAAGAATGGAATGGATCGAAGAGCGATGCC	
AHSV-4	(151) GGTGCAGTTCCACCTTATACGAAGAATGGAATGGACCGAAGAGCGATGCC	
R4-2 <sub>4,5,7,10</sub>	(151) GGTGCAGTTCCACCTTATACGAAGAATGGAATGGACCGAAGAGCGATGCC	
R4-2 <sub>7,10</sub>	(151) GGTGCAGTTCCACCTTATACGAAGAATGGAATGGACCGAAGAGCGATGCC	
R4-2 <sub>10</sub>	(151) GGTGCAGTTCCACCTTATACGAAGAATGGAATGGACCGAAGAGCGATGCC	
R3-2 <sub>5,10</sub>	(151) GGTGCAGTTCCACCTTATACGAAGAATGGAATGGACCGAAGAGCGATGCC	
R3-2 <sub>3,5</sub>	(151) GGTGCAGTTCCACCTTATACGAAGAATGGAATGGACCGAAGAGCGATGCC	
	201	250
AHSV-2	(201) TTCTTACCAAGGATAACGACTTGGATGTTGGAGTTAGAGATTTGCCTT	
AHSV-3	(201) TTCTTACCAAGGATAACAACACTTGGATGTTGGAGTTAGAGATTTGCCTT	
AHSV-4	(201) TTCTTACCAAGGATAACAACACTTGGATGTTGGAGTTAGAGATTTGCCTT	
R4-2 <sub>4,5,7,10</sub>	(201) TTCTTACCAAGGATAACAACACTTGGATGTTGGAGTTAGAGATTTGCCTT	
R4-2 <sub>7,10</sub>	(201) TTCTTACCAAGGATAACAACACTTGGATGTTGGAGTTAGAGATTTGCCTT	
R4-2 <sub>10</sub>	(201) TTCTTACCAAGGATAACAACACTTGGATGTTGGAGTTAGAGATTTGCCTT	
R3-2 <sub>5,10</sub>	(201) TTCTTACCAAGGATAACAACACTTGGATGTTGGAGTTAGAGATTTGCCTT	
R3-2 <sub>3,5</sub>	(201) TTCTTACCAAGGATAACAACACTTGGATGTTGGAGTTAGAGATTTGCCTT	
	251	300
AHSV-2	(251) TAAAGATGAAGGGAGAACAGGGAGGCAGAAAGGGAGAAGATGGAACGAGCC	
AHSV-3	(251) TAAAGATGAAGGGAGAACAGGGAGGCAGAAAGGGAGAAGATGGAACGAGCC	
AHSV-4	(251) TAAAGATGAAGGGAGAACAGGGAGGCAGAAAGGGAGAAGATGGAACGAGCC	
R4-2 <sub>4,5,7,10</sub>	(251) TAAAGATGAAGGGAGAACAGGGAGGCAGAAAGGGAGAAGATGGAACGAGCC	
R4-2 <sub>7,10</sub>	(251) TAAAGATGAAGGGAGAACAGGGAGGCAGAAAGGGAGAAGATGGAACGAGCC	
R4-2 <sub>10</sub>	(251) TAAAGATGAAGGGAGAACAGGGAGGCAGAAAGGGAGAAGATGGAACGAGCC	
R3-2 <sub>5,10</sub>	(251) TAAAGATGAAGGGAGAACAGGGAGGCAGAAAGGGAGAAGATGGAACGAGCC	
R3-2 <sub>3,5</sub>	(251) TAAAGATGAAGGGAGAACAGGGAGGCAGAAAGGGAGAAGATGGAACGAGCC	

	301	350
AHSV-2	(301) CTAAGTGGTGGGCTCGATATGGGAAGCTGTAGAATGTATGGGGGAGGAAG	
AHSV-3	(301) CT <del>G</del> AGTGGTGGGCTCGATATGGGAAGCTGTAGAATGTATGGGGGAGGAAG	
AHSV-4	(301) CTAAGTGGTGGGCTCGATATGGG <del>C</del> AGCTGTAGAATGTATGGAGGAGGAAG	
R4-2 <sub>4,5,7,10</sub>	(301) CTAAGTGGTGGGCTCGATATGGG <del>C</del> AGCTGTAGAATGTATGGAGGAGGAAG	
R4-2 <sub>7,10</sub>	(301) CTAAGTGGTGGGCTCGATATGGG <del>C</del> AGCTGTAGAATGTATGGAGGAGGAAG	
R4-2 <sub>10</sub>	(301) CTAAGTGGTGGGCTCGATATGGG <del>C</del> AGCTGTAGAATGTATGGAGGAGGAAG	
R3-2 <sub>5,10</sub>	(301) CT <del>G</del> AGTGGTGGGCTCGATATGGGAAGCTGTAGAATGTATGGGGGAGGAAG	
R3-2 <sub>3,5</sub>	(301) CT <del>G</del> AGTGGTGGGCTCGATATGGGAAGCTGTAGAATGTATGGGGGAGGAAG	
	351	400
AHSV-2	(351) AAATGA <del>C</del> TGCGTGAGATCACCTTGGATGAGGCCGGACCATACGTAC <del>G</del> C	
AHSV-3	(351) AAATGA <del>T</del> TGCGTGAGATCACCTTGGATGAGGCCGGACCATACGTAC <del>G</del> C	
AHSV-4	(351) AAATGA <del>T</del> TGCGTGAGATCACCTTGGATGAGGCCGGACCATACGTAC <del>G</del> C	
R4-2 <sub>4,5,7,10</sub>	(351) AAATGA <del>T</del> TGCGTGAGATCACCTTGGATGAGGCCGGACCATACGTAC <del>G</del> C	
R4-2 <sub>7,10</sub>	(351) AAATGA <del>T</del> TGCGTGAGATCACCTTGGATGAGGCCGGACCATACGTAC <del>G</del> C	
R4-2 <sub>10</sub>	(351) AAATGA <del>T</del> TGCGTGAGATCACCTTGGATGAGGCCGGACCATACGTAC <del>G</del> C	
R3-2 <sub>5,10</sub>	(351) AAATGA <del>T</del> TGCGTGAGATCACCTTGGATGAGGCCGGACCATACGTAC <del>G</del> C	
R3-2 <sub>3,5</sub>	(351) AAATGA <del>T</del> TGCGTGAGATCACCTTGGATGAGGCCGGACCATACGTAC <del>G</del> C	
	401	450
AHSV-2	(401) CAAGGA <del>G</del> ACTTTCTGTTCAGAGCAATGAAAGCCGTTCAGATGATGTGGC <del>G</del>	
AHSV-3	(401) CAAGGA <del>A</del> ACTTTCTGTTCAGAGCAATGAAAGTCGTTCAGATGATGTGGC <del>A</del>	
AHSV-4	(401) CGAGGA <del>A</del> ACTTTCTGTTCAGAGTAATGAAAGTCGTTCAGA <del>G</del> ATGTGGC <del>A</del>	
R4-2 <sub>4,5,7,10</sub>	(401) CGAGGA <del>A</del> ACTTTCTGTTCAGAGTAATGAAAGTCGTTCAGA <del>G</del> ATGTGGC <del>A</del>	
R4-2 <sub>7,10</sub>	(401) CGAGGA <del>A</del> ACTTTCTGTTCAGAGTAATGAAAGTCGTTCAGA <del>G</del> ATGTGGC <del>A</del>	
R4-2 <sub>10</sub>	(401) CGAGGA <del>A</del> ACTTTCTGTTCAGAGTAATGAAAGTCGTTCAGA <del>G</del> ATGTGGC <del>A</del>	
R3-2 <sub>5,10</sub>	(401) CAAGGA <del>A</del> ACTTTCTGTTCAGAGCAATGAAAGTCGTTCAGATGATGTGGC <del>A</del>	
R3-2 <sub>3,5</sub>	(401) CAAGGA <del>A</del> ACTTTCTGTTCAGAGCAATGAAAGTCGTTCAGATGATGTGGC <del>A</del>	
	451	500
AHSV-2	(451) CGAACGACATGCTGAGTTGGT <del>A</del> AGAGATGGAGCGATAAGAATGATGAAGAA	
AHSV-3	(451) CGAACGACATGCTGAGTTGGT <del>G</del> GAGATGGAGCGATAAGAATGATGAAGAA	
AHSV-4	(451) CGAACGACATGCTGAGTTGGT <del>G</del> GAGATGGAGCGATAAGAATGATGAAGAA	
R4-2 <sub>4,5,7,10</sub>	(451) CGAACGACATGCTGAGTTGGT <del>G</del> GAGATGGAGCGATAAGAATGATGAAGAA	
R4-2 <sub>7,10</sub>	(451) CGAACGACATGCTGAGTTGGT <del>G</del> GAGATGGAGCGATAAGAATGATGAAGAA	
R4-2 <sub>10</sub>	(451) CGAACGACATGCTGAGTTGGT <del>G</del> GAGATGGAGCGATAAGAATGATGAAGAA	
R3-2 <sub>5,10</sub>	(451) CGAACGACATGCTGAGTTGGT <del>G</del> GAGATGGAGCGATAAGAATGATGAAGAA	
R3-2 <sub>3,5</sub>	(451) CGAACGACATGCTGAGTTGGT <del>G</del> GAGATGGAGCGATAAGAATGATGAAGAA	
	501	550
AHSV-2	(501) CGAACCA <del>G</del> TACGTACAGAGAGTATGTGGTGTCAAAGTGA <del>A</del> GTGATGATGATC	
AHSV-3	(501) TGAACCA <del>G</del> TACGTACAGAGAGTATGTGGTGTCAAAGTGA <del>A</del> GTGATGATGATC	
AHSV-4	(501) TGAACCA <del>G</del> TACGTACAGAGAGTATGTGGTGTCAAAGTGA <del>A</del> GTGATGATC	
R4-2 <sub>4,5,7,10</sub>	(501) TGAACCA <del>G</del> TACGTACAGAGAGTATGTGGTGTCAAAGTGA <del>A</del> GTGATGATC	
R4-2 <sub>7,10</sub>	(501) TGAACCA <del>G</del> TACGTACAGAGAGTATGTGGTGTCAAAGTGA <del>A</del> GTGATGATC	
R4-2 <sub>10</sub>	(501) TGAACCA <del>G</del> TACGTACAGAGAGTATGTGGTGTCAAAGTGA <del>A</del> GTGATGATC	
R3-2 <sub>5,10</sub>	(501) TGAACCA <del>G</del> TACGTACAGAGAGTATGTGGTGTCAAAGTGA <del>A</del> GTGATGATC	
R3-2 <sub>3,5</sub>	(501) TGAACCA <del>G</del> TACGTACAGAGAGTATGTGGTGTCAAAGTGA <del>A</del> GTGATGATC	
	551	584
AHSV-2	(551) AATCTGATGAGGATCACGAGATTGGGAGTACAGA	
AHSV-3	(551) AATCTGATGAGGATCACGAGGTTGGGAGTACAGA	
AHSV-4	(551) AATCTGATGAGGATCACGAGGTTGGGAGTACAGA	
R4-2 <sub>4,5,7,10</sub>	(551) AATCTGATGAGGATCACGAGGTTGGGAGTACAGA	
R4-2 <sub>7,10</sub>	(551) AATCTGATGAGGATCACGAGGTTGGGAGTACAGA	
R4-2 <sub>10</sub>	(551) AATCTGATGAGGATCACGAGGTTGGGAGTACAGA	
R3-2 <sub>5,10</sub>	(551) AATCTGATGAGGATCACGAGGTTGGGAGTACAGA	
R3-2 <sub>3,5</sub>	(551) AATCTGATGAGGATCACGAGGTTGGGAGTACAGA	

### VP6 gene (Segment 9)

		113
AHSV-2	(113) GATAGGACAGGCCGC CGCAGCGGA	162
AHSV-3	(113) GATAGGATTGGCGCTGCAGCGGA	
AHSV-4	(113) GATAGGACAGGCCGC TGCGAGCGGA	
R4-2 <sub>4,5,7,10</sub>	(113) GATAGGACAGGCCGC TGCGAGCGGA	
R4-2 <sub>7,10</sub>	(113) GATAGGACAGGCCGC TGCGAGCGGA	
R4-2 <sub>10</sub>	(113) GATAGGACAGGCCGC TGCGAGCGGA	
R3-2 <sub>5,10</sub>	(113) GATAGGATTGGCGCTGCAGCGGA	
R3-2 <sub>3,5</sub>	(113) GATAGGATTGGCGCTGCAGCGGA	
	163	212
AHSV-2	(163) AAAGGCTGGAGGGGGCGATA CGGATTGGAGGATTAGC	
AHSV-3	(163) AAAGGCTGGAGGGGGCGATA CGGATTGGAGGATTAGCA	
AHSV-4	(163) AAAGGCTGGAGGGGGCGATA CGGATTGGAGGATTAGCA	
R4-2 <sub>4,5,7,10</sub>	(163) AAAGGCTGGAGGGGGCGATA CGGATTGGAGGATTAGCA	
R4-2 <sub>7,10</sub>	(163) AAAGGCTGGAGGGGGCGATA CGGATTGGAGGATTAGCA	
R4-2 <sub>10</sub>	(163) AAAGGCTGGAGGGGGCGATA CGGATTGGAGGATTAGCA	
R3-2 <sub>5,10</sub>	(163) AAAGGCTGGAGGGGGCGATA CGGATTGGAGGATTAGCA	
R3-2 <sub>3,5</sub>	(163) AAAGGCTGGAGGGGGCGATA CGGATTGGAGGATTAGCA	
	213	262
AHSV-2	(213) TTGCAGACTTTGTGAAGAAGAAGATCGGAGTTGAAGTCAGGTGTT	
AHSV-3	(213) TTGCAGACTTTGTGAAGAAGAAGATCGGAGTTGAAGTCAGGTGTTTCT	
AHSV-4	(213) TTGCAGACTTTGTGAAGAAGAAGATCGGAGTTGAAGTCAGGTGTTTCT	
R4-2 <sub>4,5,7,10</sub>	(213) TTGCAGACTTTGTGAAGAAGAAGATCGGAGTTGAAGTCAGGTGTTTCT	
R4-2 <sub>7,10</sub>	(213) TTGCAGACTTTGTGAAGAAGAAGATCGGAGTTGAAGTCAGGTGTTTCT	
R4-2 <sub>10</sub>	(213) TTGCAGACTTTGTGAAGAAGAAGATCGGAGTTGAAGTCAGGTGTTTCT	
R3-2 <sub>5,10</sub>	(213) TTGCAGACTTTGTGAAGAAGAAGATCGGAGTTGAAGTCAGGTGTTTCT	
R3-2 <sub>3,5</sub>	(213) TTGCAGACTTTGTGAAGAAGAAGATCGGAGTTGAAGTCAGGTGTTTCT	
	263	312
AHSV-2	(263) AAAGGAATGAGCAACTTATTACTGTAGATAAGTCATTGCTTGAGCGGGG	
AHSV-3	(263) AAAGGAATGAGCAACTTATTACTGTAGATAAGTCATTGCTTGAGCGGGG	
AHSV-4	(263) AAAGGAATGAGCAACTTATTACTGTAGATAAGTCATTGCTTGAGCGGGG	
R4-2 <sub>4,5,7,10</sub>	(263) AAAGGAATGAGCAACTTATTACTGTAGATAAGTCATTGCTTGAGCGGGG	
R4-2 <sub>7,10</sub>	(263) AAAGGAATGAGCAACTTATTACTGTAGATAAGTCATTGCTTGAGCGGGG	
R4-2 <sub>10</sub>	(263) AAAGGAATGAGCAACTTATTACTGTAGATAAGTCATTGCTTGAGCGGGG	
R3-2 <sub>5,10</sub>	(263) AAAGGAATGAGCAACTTATTACTGTAGATAAGTCATTGCTTGAGCGGGG	
R3-2 <sub>3,5</sub>	(263) AAAGGAATGAGCAACTTATTACTGTAGATAAGTCATTGCTTGAGCGGGG	
	313	
AHSV-2	(313) TGGGTTAGGG	
AHSV-3	(313) TGGGTTAGGG	
AHSV-4	(313) TGGGTTAGGA	
R4-2 <sub>4,5,7,10</sub>	(313) TGGGTTAGGA	
R4-2 <sub>7,10</sub>	(313) TGGGTTAGGA	
R4-2 <sub>10</sub>	(313) TGGGTTAGGA	
R3-2 <sub>5,10</sub>	(313) TGGGTTAGGG	
R3-2 <sub>3,5</sub>	(313) TGGGTTAGGG	



### NS3 gene (Segment 10)

		351	400
AHSV-2	(165)	TATGTTTATTGGCGGAACGTAACTATGGCTACTTCCTCTAGTTGGAGGTA	
AHSV-3	(165)	GATCTTATGAGCGGGTGCCTAACGATGGCTACCTCGATGGCGGGCGGGT	
AHSV-4	(351)	GATCTTATTAGCGGATGTGTGACGTTGGAACATCGATGGTTGGAGGTA	
R4-2 <sub>4,5,7,10</sub>	(165)	TATGTTTATTGGCGGAACGTAACTATGGCTACTTCCTCTAGTTGGAGGTA	
R4-2 <sub>7,10</sub>	(165)	TATGTTTATTGGCGGAACGTAACTATGGCTACTTCCTCTAGTTGGAGGTA	
R4-2 <sub>10</sub>	(165)	TATGTTTATTGGCGGAACGTAACTATGGCTACTTCCTCTAGTTGGAGGTA	
R3-2 <sub>5,10</sub>	(165)	TATGTTTATTGGCGGAACGTAACTATGGCTACTTCCTCTAGTTGGAGGTA	
		401	450
AHSV-2	(215)	TGTCAATCGTTGATGAGGATATTGCTAAGCAAGGGCGTTTAATGGAAAA	
AHSV-3	(215)	TAACGATTATTGATAATGAAATATATGAAGACCT-----TAGTGGAGAT	
AHSV-4	(401)	TAAGTATTGTCGATAGCGAAATATTGAAGATTA-----TAAGGAGAAC	
R4-2 <sub>4,5,7,10</sub>	(215)	TGTCAATCGTTGATGAGGATATTGCTAAGCAAGGGCGTTTAATGGAAAA	
R4-2 <sub>7,10</sub>	(215)	TGTCAATCGTTGATGAGGATATTGCTAAGCAAGGGCGTTTAATGGAAAA	
R4-2 <sub>10</sub>	(215)	TGTCAATCGTTGATGAGGATATTGCTAAGCAAGGGCGTTTAATGGAAAA	
R3-2 <sub>5,10</sub>	(215)	TGTCAATCGTTGATGAGGATATTGCTAAGCAAGGGCGTTTAATGGAAAA	
		451	500
AHSV-2	(265)	GAGGATTGGCTGTCAAAAACGGTCCATGGTTAAATTGTTATGTACTAC	
AHSV-3	(259)	---GGTGGCTGTCAAGAGCGATTACACGGTTGAATTGCTGTGTACAC	
AHSV-4	(445)	---GATTGGTTAGTGAAAACGATACATGGCTGAATTGTTATGTACAC	
R4-2 <sub>4,5,7,10</sub>	(265)	GAGGATTGGCTGTCAAAAACGGTCCATGGTTAAATTGTTATGTACTAC	
R4-2 <sub>7,10</sub>	(265)	GAGGATTGGCTGTCAAAAACGGTCCATGGTTAAATTGTTATGTACTAC	
R4-2 <sub>10</sub>	(265)	GAGGATTGGCTGTCAAAAACGGTCCATGGTTAAATTGTTATGTACTAC	
R3-2 <sub>5,10</sub>	(265)	GAGGATTGGCTGTCAAAAACGGTCCATGGTTAAATTGTTATGTACTAC	
		501	550
AHSV-2	(315)	GATGCTACTGGCAGCGAATAAAATATCGGAAAGGTGAGAGAAGAGATTG	
AHSV-3	(306)	TATGTTGTTAGCGGCTGGAAAAATATCAGATAAAATACAGGAGGAGATCT	
AHSV-4	(492)	AGTTTTGTTGGCGCGGGTAAGATTCTGATAAAATACAAGAGGAGATT	
R4-2 <sub>4,5,7,10</sub>	(315)	GATGCTACTGGCAGCGAATAAAATATCGGAAAGGTGAGAGAAGAGATTG	
R4-2 <sub>7,10</sub>	(315)	GATGCTACTGGCAGCGAATAAAATATCGGAAAGGTGAGAGAAGAGATTG	
R4-2 <sub>10</sub>	(315)	GATGCTACTGGCAGCGAATAAAATATCGGAAAGGTGAGAGAAGAGATTG	
R3-2 <sub>5,10</sub>	(315)	GATGCTACTGGCAGCGAATAAAATATCGGAAAGGTGAGAGAAGAGATTG	
		551	600
AHSV-2	(365)	CGAGGACAAAAGAGACATCGCGAAAGACGATCGTACGTATCAGCTGG	
AHSV-3	(356)	CAAGCACAAAGCGGGATATAGCGAAGAGAGAATCATATGTTCCGGCG	
AHSV-4	(542)	CACAGACAAAGCGTGATATTGCGAAAGAGAGTCTTACGTATCTGCGGCG	
R4-2 <sub>4,5,7,10</sub>	(365)	CGAGGACAAAAGAGACATCGCGAAAGACGATCGTACGTATCAGCTGG	
R4-2 <sub>7,10</sub>	(365)	CGAGGACAAAAGAGACATCGCGAAAGACGATCGTACGTATCAGCTGG	
R4-2 <sub>10</sub>	(365)	CGAGGACAAAAGAGACATCGCGAAAGACGATCGTACGTATCAGCTGG	
R3-2 <sub>5,10</sub>	(365)	CGAGGACAAAAGAGACATCGCGAAAGACGATCGTACGTATCAGCTGG	
		601	650
AHSV-2	(415)	ACGATGTCTTGGGATGGCGATAAGCGTAACCTATTACGAGATGTA	AAAAAA
AHSV-3	(406)	AGTATGTCTTGGAGTGGGATACGAGCGTTCTATTAAAAGAGGTAA	AAAAA
AHSV-4	(592)	AGTATGTCTGGGATGGAGATACTGAAGTATTATACAGGCAATTAAAGTA	
R4-2 <sub>4,5,7,10</sub>	(415)	ACGATGTCTTGGGATGGCGATAAGCGTAACCTATTACGAGATGTA	AAAAAA
R4-2 <sub>7,10</sub>	(415)	ACGATGTCTTGGGATGGCGATAAGCGTAACCTATTACGAGATGTA	AAAAAA
R4-2 <sub>10</sub>	(415)	ACGATGTCTTGGGATGGCGATAAGCGTAACCTATTACGAGATGTA	AAAAAA
R3-2 <sub>5,10</sub>	(415)	ACGATGTCTTGGGATGGCGATAAGCGTAACCTATTACGAGATGTA	AAAAAA
		651	
AHSV-2	(465)	TGGAGACTAGCGG	
AHSV-3	(456)	TGGCGACAGCTAG	
AHSV-4	(642)	TGGCGATAGCTAG	
R4-2 <sub>4,5,7,10</sub>	(465)	TGGAGACTAGCGG	
R4-2 <sub>7,10</sub>	(465)	TGGAGACTAGCGG	
R4-2 <sub>10</sub>	(465)	TGGAGACTAGCGG	
R3-2 <sub>5,10</sub>	(465)	TGGAGACTAGCGG	

## APPENDIX B

Amino acid sequence alignment of NS3 of AHSV-2, AHSV-3 and AHSV-4. Dots indicate identity to AHSV-2 82/61 NS3.

AHSV-2	82/61	1	50
AHSV-3	M322/97	MNLASISQSYMSHNENERSIVPYIPPPY-HPTAPALAVSASQMETMSLGI	
AHSV-4	HS39/97	.S..T.AEN..M..G.Q.A....V....AYAN..TLGGQ.GE..S.....	
		....T.AKN.SM..GESGA....V....NFAS..TFSQRT....SV....	
		51	100
AHSV-2	82/61	LNQAMSSAGASGALKDEKAAGAVAELRDPEPIRKIKRRVGIQTLKTL	
AHSV-3	M322/97	.....TT...R.....M.....Q..KH..LR...H.	
AHSV-4	HS39/97	.....TT.....M.....Q..KQ...R...N.	
		101	150
AHSV-2	82/61	KVELSGMRRKKLILKIIIMFICANVTMATSIVGGMSIVDEDIAKHLAFDGK	
AHSV-3	M322/97	.I..AS...RYA..RVVI.MSGC.....MA..LT.I.NE.YED.SG..-	
AHSV-4	HS39/97	.M..AT.....SA...MI..SGC..L...M...L...DE.LRDYKNND-	
		151	200
AHSV-2	82/61	GDWVSKTVHGLNLLCTTMLLAANKISEKVREEIARTKRDIAKRQSYVSAA	
AHSV-3	M322/97	--.L...I.....G...D.IQ...S.....E.....	
AHSV-4	HS39/97	--.LM..I.....V....G...D.MQ...S.....E.....	
		201	220
AHSV-2	82/61	TMSWDGDSVTLLRDVKYGD-	
AHSV-3	M322/97	S...S..TSV..KE.....S	
AHSV-4	HS39/97	S...S..TEM..QGI...ES	